Title
Laminin signals initiate the reciprocal loop that informs breast-specific gene expression and homeostasis by activating NO, p53 and microRNAs.

Permalink
https://escholarship.org/uc/item/85t2r40p

Journal
eLife, 7

ISSN
2050-084X

Authors
Furuta, Saori
Ren, Gang
Mao, Jian-Hua
et al.

Publication Date
2018-03-21

DOI
10.7554/eLife.26148

Peer reviewed
Laminin signals initiate the reciprocal loop that informs breast-specific gene expression and homeostasis by activating NO, p53 and microRNAs

Saori Furuta1,2†*, Gang Ren2, Jian-Hua Mao1, Mina J Bissell1*

1Division of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, United States; 2Department of Cancer Biology, College of Medicine & Life Sciences, University of Toledo Health Science Campus, Toledo, United States

Abstract
How mammalian tissues maintain their architecture and tissue-specificity is poorly understood. Previously, we documented both the indispensable role of the extracellular matrix (ECM) protein, laminin-111 (LN1), in the formation of normal breast acini, and the phenotypic reversion of cancer cells to acini-like structures in 3-dimensional (3D) gels with inhibitors of oncogenic pathways. Here, we asked how laminin (LN) proteins integrate the signaling pathways necessary for morphogenesis. We report a surprising reciprocal circuitry comprising positive players: laminin-5 (LN5), nitric oxide (NO), p53, HOXD10 and three microRNAs (miRNAs) — that are involved in the formation of mammary acini in 3D. Significantly, cancer cells on either 2-dimensional (2D) or 3D and non-malignant cells on 2D plastic do not produce NO and upregulate negative players: NFkB, EIF5A2, SCA1 and MMP-9 — that disrupt the network. Introducing exogenous NO, LN5 or individual miRNAs to cancer cells reintegrates these pathways and induces phenotypic reversion in 3D. These findings uncover the essential elements of breast epithelial architecture, where the balance between positive- and negative-players leads to homeostasis.

Introduction
p53 is an extensively characterized regulator of gene expression in the context of malignant transformation and is aberrant in almost all cancer types. Many p53 studies have been performed in cells cultured in 2D conditions. Despite the extensive literature on p53 and its myriad of functions, little is known about what regulates p53 activity in higher organisms in vivo or about how p53 might regulate physiological tissue functions in 3D cultures (Barcellos-Hoff et al., 1989; Petersen et al., 1992; Bissell et al., 2005; Lee et al., 2007). ECM proteins, in particular LNs (Miner and Yurchenco, 2004), compose another important class of regulators that play a role in glandular tissue morphogenesis. Whether or how these two crucial regulators of gene expression intersect in tissue morphogenesis and homeostasis has not been examined.

To explore the possibility of such an interaction as an element of tissue-specificity, we utilized the HMT3522 cancer progression series of human mammary epithelial cells (MECs) (Briand et al., 1987; Briand et al., 1996; Rizki et al., 2008). This unique series comprise both primary normal epithelial cells or non-malignant cells (S1) derived from reduction mammoplasty, and their malignant counterpart (T4-2), which were derived without external oncogenic agents after prolonged cultivation in defined medium that lacked epidermal growth factor (EGF), followed by xenografts in animals (Briand et al., 1987). Non-malignant and malignant MECs and organoids are readily distinguished.

*For correspondence:
saori.furuta@utoledo.edu (SF); MJBissell@lbl.gov (MJB)

Present address: 1Department of Cancer Biology, College of Medicine & Life Sciences, University of Toledo Health Science Campus, Toledo, OH, United States

Competing interests: The authors declare that no competing interests exist.

Funding: See page 35

Received: 21 February 2017
Accepted: 21 November 2017
Published: 21 March 2018

Reviewing editor: Valerie Horsley, Yale University, United States

© Copyright Furuta et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
by their colony structures in 3D LN1-rich ECM gels (lrECM) (Petersen et al., 1992). Non-malignant mammary cells form polarized colonies resembling normal acini of the breast (Barcellos-Hoff et al., 1989), whereas malignant cells form disorganized, tumor-like structures (Petersen et al., 1992; Lee et al., 2007; Rizki et al., 2008). However, if the architecture of colonies is restored in LN1 gels by downmodulating receptors such as integrins and EGFR, or other involved oncogenic pathways to a level found in normal cells, every single malignant cell can – despite mutations – be turned into a healthy-looking cell. These cells form a normal-looking tissue through a process called reversion. Until now, it was not known which signals help normal breast tissue to form, and how cancerous cells revert into a ‘normal’ shape.

To investigate this, Furuta et al. used a unique series of breast cells from a woman who underwent breast reduction. The cells taken from the discarded tissue had been previously grown by a different group of researchers in a specific way to ensure that both normal and eventual cancer cells were from the same individual. Furuta et al. then put these cells in the type of laminin found in extracellular matrix. The other set of cells used consisted of the same cancerous cells that had been reverted to normal-looking cells.

Analysis of the three cell sets identified 60 genes that were turned down in reverted cancer cells to a level found in healthy cells, as well as 10 microRNAs that potentially target these 60 genes. A database search suggested that three of these microRNAs, which are absent in cancer cells, are necessary for healthy breast cells to form organized structures. Using this as a starting point, Furuta et al. discovered a signaling loop that was previously unknown and that organizes breast cells into healthy looking tissue.

This showed that laminins help to produce nitric oxide, an important signaling molecule that activates several specific proteins inside the breast cells and restores the levels of the three microRNAs. These, in turn, switch off two genes that are responsible for activating an enzyme that can chop the laminins. Since the two genes are deactivated in the reverted cancer cells, the laminins remain intact and the cells can form organized structures. These findings suggest that if any of the components of the loop were missing, the cells would start to form cancerous clumps again. Reverting the cancer cells in the presence of laminins, however, could help cancer cells to form ‘normal’ structures again.

These findings shed new light on how the extracellular matrix communicates with proteins in the nucleus to influence how single cells form breast tissues. It also shows that laminins are crucial for generating signals that regulate both form and function of specific tissues. A better understanding of how healthy and cancerous tissues form and re-form may in the future help to develop new cancer treatments.

DOI: https://doi.org/10.7554/eLife.26148.002
signaling inhibitors, we identified a subset of 60 genes that had similar expression patterns in S1 and in all of the T4-2 Rev cells (Bissell et al., 2005; Becker-Weimann et al., 2013), as well as 10 miRNAs that could potentially target these 60 genes. Among the 10 miRNAs, we specifically focused on miR-34c-5p, −30e, and −144, which are dramatically downmodulated in many breast tumors (Lu et al., 2005).

Restoration of the miRNA caused phenotypic reversion of T4-2 cells in lrECM. While studying the signaling cascades that involve these three miRNAs, we identified a reciprocal regulatory network – comprising LN1 and LN5, NO, p53, HOXD10, NFκB, the three miRNAs, EIF5A2, SCA1, and MMP-9 – which connects the ECM-laminins and the nuclear transcription factors (TFs), most possibly via a newly discovered nuclear tunnel (Jorgens et al., 2017), to execute breast morphogenetic programs. Our results shed light on a completely novel and intricate reciprocal loop for breast acinar morphogenesis through a reiterative activation and suppression of regulatory molecules necessary to maintain the differentiated state in 3D and to prevent malignant conversion.

Results

Identification of miRNAs involved in the formation of mammary acini

Non-malignant S1 cells form apico-basally polarized acini in lrECM while conversely, malignant T4-2 cells form disorganized colonies (Petersen et al., 1992). We showed initially that inhibitory antibodies to beta-1 integrin reverted the malignant cells to ‘normal’ phenotype (Figure 1a) (Weaver et al., 1997). Inhibiting any of a dozen different oncogenic pathway components, including EGFR, PI3K and MMP-9, could revert breast cancer cells (Figure 1a−1c) (Bissell et al., 2005; Beliveau et al., 2010; Becker-Weimann et al., 2013). Such cross-modulation suggested the existence of central common integrators. Array analyses of the five most prominent reverting pathways identified 60 genes that were low in S1, and co-downregulated in T4-2 Rev cells (Figure 1d, Table 1) (Bissell et al., 2005), leading us to suspect that the common regulators would be miRNAs.

miRNA expression profiling of the S1, T4-2, and T4-2 Rev cells in lrECM identified a list of 30 miRNAs, the expression of which was anti-correlated with that of the 60 genes (Figure 1d, Table 2). Using a miRNA target database (microRNA.org), we predicted miRNAs that could potentially target the 60 genes. By combining these two lists, we chose 10 validated miRNAs (Figure 2a) each of which could potentially target at least 10 out of the 60 genes (Table 3).

Using published patient sample analyses, we selected three miRNAs: miR-34c-5p, −30e and −144, that were found to be downmodulated significantly in breast tumors and tumor cell lines (Figure 1—figure supplement 1)(GSE25464) (Lu et al., 2005). By in situ hybridization of tissue arrays containing 40 breast tumors vs. normal tissues, we confirmed a significant reduction of the three miRNAs in tumors (Figure 2b, c). Re-expression of each of the three miRNAs in T4-2 cells led to dramatic growth inhibition in soft agar (Figure 2d, Figure 2—figure supplement 1b) and caused phenotypic reversion in lrECM (Figure 2e, Figure 2—figure supplement 1c). Introduction of each of the three miRNAs into metastatic MDA-MB-231 breast cancer cells also led to severe growth impairment in lrECM (Figure 2f, Figure 2—figure supplement 1d). These results suggest that the three miRNAs are involved in inhibiting tumor cell growth and, by implication, in the maintenance of non-malignant cell behavior.

EIF5A2 and SCA1 are the targets of the three identified miRNAs

A search of the miRNA target database (microRNA.org) identified EIF5A2 and SCA1 as the only common target genes of the three miRNAs among the 60 genes that were modulated by each of five reverting agents (Table 4, Figure 1). To validate this, we performed RT-PCR for EIF5A2 and SCA1 in T4-2 cells before and after miRNA expression. Endogenous levels of the two proteins were high in T4-2 cells compared to those in S1 cells, but as expected, were downmodulated in T4-2 Rev cells that were reverted either with a reverting agent or upon restoration of any of the three miRNAs (Figure 3a). Thus, each miRNA acted like a reverting agent, similar to the five other reverting agents we have reported on previously (Figure 3a; Figure 1a−c) (Bissell et al., 2005; Beliveau et al., 2010; Becker-Weimann et al., 2013). Importantly, depletion of either EIF5A2 or SCA1 in T4-2 cells with shRNA (Figure 3—figure supplement 1a) also caused phenotypic reversion (Figure 3b, Figure 3—figure supplement 1b). To ensure that this is not an off-target effect, we
Figure 1. Identification of miRNAs linked to phenotypic reversion of human breast-cancer cells. (a) Scheme of progression of non-malignant HMT3522-S1 cells to malignant T4-2 cells and of reversion of T4-2 cells to an S1-like phenotype in the presence of a reverting agent. (b) S1, T4-2 and T4-2 Rev cells with AG1478 in lrECM. Cells are stained for integrin α6 (red), β-catenin (green) and nuclei (blue). Scale bars: 20 μm. Replicate experiments (n = 3) were performed, and representative data are shown. (c) A scheme of modulation of a single oncogenic pathway for phenotypic reversion of tumor cells. Five pathways chosen for gene and miRNA arrays are indicated with blue asterisks (*). (d) Screening miRNAs linked to phenotypic reversion. (Top left) Gene arrays (n = 5, GSE50444 [Becker-Weimann et al., 2013]) clustered 60 genes that are downmodulated in S1 and T4-2 Rev.
restored EIF5A2 and SCA1 in T4-2 cells that were overexpressing the miRNAs. In these T4-2 cells we overexpressed cDNAs of EIF5A2 or SCA1 that lacked miRNA binding sites because the three miRNAs bind only to the 3'UTR of the two target genes (Table 5). Overexpression was confirmed by western analysis (Figure 3—figure supplement 1c). Restoration of EIF5A2 or SCA1 severely impaired tumor-cell reversion, validating the importance of the inactivation of these two target genes for normal functional differentiation of breast acini (Figure 3—figure supplement 1d and e). These results demonstrate that the miRNA database correctly predicted EIF5A2 or SCA1 as the target genes of the three miRNAs.

Reversion of breast tumor cells to normal phenotype requires upregulation of HOXD10 and downregulation of NFκB

To determine the regulators of the three miRNAs, we generated reporter constructs in which the luciferase gene was fused to the miRNA gene promoters, containing 3–0, 2–0 and 1–0 kb regions from the transcription start site (Figure 3—figure supplement 2a). The activity of the 1–0 kb region for miR-34c and the 3–0 kb region for both miR-30e and -144 was high in S1 and T4-2 Rev cells, but not in T4-2 cells (Figure 3c). In addition, we generated reporter constructs containing non-overlapping 3–2, 2–1 and 1–0 kb fragments of the miRNA promoters from the transcription start site (Figure 3—figure supplement 2b). The activity of the 1–0 kb region for miR-34c and the 3–2 kb region for both miR-30e and -144 was high in S1 and T4-2 Rev cells (Figure 3d).

To determine which TFs bound to these critical regions, we analyzed the PROMO database (Farré et al., 2003) and identified multiple high-confidence binding sites for HOXD10 and NFκB (% dissimilarity <15%; genomic frequency <1×10⁻⁴) (Figure 4—figure supplement 1a, Table 6) (Farré et al., 2003). We had shown previously that overexpression of HOXD10 or downmodulation of NFκB phenotypically reverses T4-2 cells (Becker-Weimann et al., 2013; Chen et al., 2009). As predicted, HOXD10 was high in S1 and T4-2 Rev cells compared to T4-2 cells (Figure 4a). By contrast, activation of NFκB, as measured by Ser536 phosphorylation of the p65 subunit that causes its nuclear translocation (Sasaki et al., 2005), was elevated in T4-2 cells and downmodulated in S1 and T4-2 Rev cells (Figure 4a). To show that these two TFs regulate the miRNAs in opposite directions, we generated T4-2 cells that were depleted of either p65 or p50, and its unprocessed precursor, p100, a subunit of NFκB. We also overexpressed HOXD10 in T4-2 cells (Figure 4—figure supplement 1b). In all these conditions, the activity of the miRNA promoters was elevated in the same regions as those described above (Figure 4b, Figure 3—figure supplement 1d). Northern analysis confirmed the increase of miRNA expression, allowing the formation of basally polarized colonies in lrECM (Figure 4c and d, Figure 4—figure supplement 1c), which were analogous to colonies of miRNAs-expressing T4-2 cells (Figure 2c). These results highlight the importance of the ratios and balance of different regulatory genes in maintaining normal architecture.

To prove that HOXD10 and NFκB do indeed bind the promoters of the three miRNAs, we performed chromatin immunoprecipitation (ChIP) analyses. We found that HOXD10 bound the promoters of the three miRNAs in S1 and T4-2 Rev cells, but not in T4-2 cells, whereas the NFκB p65 subunit bound the same regions in T4-2 cells, but not in S1 and T4-2 Rev cells (Figure 4e, Figure 4—figure supplement 1d).

To ascertain the functional consequence of the above experiment, we used the decoy technology described by Osako et al. (Osako et al., 2012). These decoys were derived from their respective binding sequences in each miRNA promoter (Table 7). For T4-2 cells, which have a high level of endogenous NFκB (Figure 4a), we expressed NFκB decoys; for T4-2 cells that we overexpressed
**Table 1.** List of 60 genes downregulated in T4-2 revertants to the level found in S1 but unmodulated in T4-2 cells in lrECM (p-value < 0.05 was considered significant) (*Rizki et al., 2008*).

| Ensembl gene ID  | Ensembl transcript ID | Gene name |
|------------------|-----------------------|-----------|
| ENSG00000107796  | ENST00000224784       | ACTA2     |
| ENSG00000109321  | ENST00000264487       | AREG      |
| ENSG00000102606  | ENST00000317133       | ARHGEF7   |
| ENSG00000134107  | ENST00000256495       | BHLHB2    |
| ENSG00000101189  | ENST00000217161       | C20orf20  |
| ENSG00000115009  | ENST00000358813       | CCL20     |
| ENSG00000161570  | ENST00000293272       | CCL5      |
| ENSG00000169583  | ENST00000224152       | CLIC3     |
| ENSG00000165959  | ENST00000298912       | CLMN      |
| ENSG00000176390  | ENST00000324238       | CRLF3     |
| ENSG00000105246  | ENST00000221847       | EBI3      |
| ENSG00000163577  | ENST00000295822       | EIF5A2    |
| ENSG00000187266  | ENST00000222139       | EPOR      |
| ENSG00000085832  | ENST00000262674       | EPS15     |
| ENSG00000124882  | ENST00000244869       | EREG      |
| ENSG00000197930  | ENST00000359133       | ERO1L     |
| ENSG00000149573  | ENST00000278937       | EVA1      |
| ENSG00000141524  | ENST00000322933       | EVER1     |
| ENSG00000185862  | ENST00000330927       | EVI2B     |
| ENSG00000180263  | ENST00000343958       | FGD6      |
| ENSG00000088726  | ENST00000314124       | FLJ11036  |
| ENSG00000137312  | ENST00000259846       | FLOT1     |
| ENSG00000100031  | ENST00000248923       | GGT1      |
| ENSG00000149435  | ENST00000286890       | GGTlA4    |
| ENSG00000051620  | ENST000002058691       | HEBP2     |
| ENSG00000178922  | ENST00000326220       | HT036     |
| ENSG00000172183  | ENST00000306072       | ISG20     |
| ENSG00000105655  | ENST00000357050       | ISYNA1    |
| ENSG00000119698  | ENST00000304338       | KIAA1622  |
| ENSG00000134121  | ENST00000256509       | L1CAM     |
| ENSG00000110492  | ENST00000359803       | MDK       |
| ENSG00000146232  | ENST00000275015       | NFKBIE    |
| ENSG00000008517  | ENST0000008180        | NK4       |
| ENSG00000157045  | ENST00000287706       | NTAN1     |
| ENSG00000135124  | ENST00000356268       | P2R x 4   |
| ENSG00000110218  | ENST00000227638       | PANX1     |
| ENSG00000145431  | ENST00000274071       | PDGFC     |
| ENSG00000166289  | ENST00000299373       | PLEKHF1   |
| ENSG000000083444  | ENST00000196061       | PLOD      |
| ENSG00000107758  | ENST00000342558       | PPP3CB    |
| ENSG00000011304  | ENST00000350092       | PTBP1     |
| ENSG00000073756  | ENST00000186982       | PTGS2     |
| ENSG00000118508  | ENST00000237295       | RAB32     |
| ENSG00000013588  | ENST0000014914        | RAI3      |
HOXD10 (Figure 4—figure supplement 1b), we employed HOXD10 decoys. Any alteration in the promoter activity after expressing a particular decoy would indicate that the TF was bound and sequestered by the decoy. To test for sequence-specific binding of the TFs, we engineered decoys harboring point mutations in T4-2 cells. The expression of wild-type NFκB decoys, but not mutant decoys, derepressed the promoter activities, showing that the wild-type decoys bound and sequestered NFκB, whereas the mutant decoys did not. The procedure was repeated for HOXD10 with similar conclusions (Figure 4—figure supplement 1e). Collectively, these results demonstrate that HOXD10 and NFκB directly bind the specific sequences in miRNA promoters in a mutually exclusive manner to regulate miRNA expression for restoration of breast acinar architecture.

p53 is another essential element in mammary acinar formation and tumor-cell reversion

p53 is a potent inhibitor of NFκB (Webster and Perkins, 1999; Murphy et al., 2011). Because p53 activity in tumors is extremely high, it is often assumed that little or no p53 is present in normal tissues. We found appreciable levels of wild-type p53 in the epithelial compartment of sections of normal breast tissues but not in the stroma (Figure 9—figure supplement 1). In 3D cultures of S1 and T4-2 Rev cells, we found appreciable levels of Ser20-phosphorylated p53 (pSer20-p53), which stabilizes (Chehab et al., 1999) and enhances the transactivation activity of p53 (Jabbur et al., 2000). This was also the case when either of the miRNAs were overexpressed in T4-2 cells or when their inhibitory target, EIF5A2 or SCA1, was depleted (Figure 5a). The expression of the p53-regulated genes, p21, GADD45 and DRAM, was elevated in S1 and all T4-2 Rev cells (Figure 5a).

Whether p53 is both the direct inhibitor of NFκB and an activator of HOXD10 was examined by overexpressing the dominant-negative p53 (DNp53) (Harvey et al., 1995) in S1 cells. This particular mutant of p53 was reported to effectively abolish tumor suppression and transcriptional activity of the endogenous wild-type p53, leading to enhanced tumor growth, even in heterozygous mice. In S1 cells that overexpressed DNp53, HOXD10 level plummeted as NFκB activity, measured by Ser536 phosphorylation of the p65 subunit, increased over the levels seen in control S1 cells or S1 cells overexpressing the wild-type p53 (Figure 5b).

As expected, expression of DNp53 prevented S1 cells from forming polarized quiescent acini in lrECM (Figure 5c, Figure 5—figure supplement 1a). Similarly, RNAi-mediated depletion of the wild-type p53 in S1 or MCF10A cells abrogated acinar formation (Figure 5d and e, Figure 5—figure supplement 1b).
Furthermore, inhibition of p53 activity with a specific inhibitor, α-pifithrin (Komarov et al., 1999), rendered T4-2 cells resistant to phenotypic reversion by any of the reverting agents tested (Bissell et al., 2005; Lee et al., 2007, 2012) or by re-expression of any of the three miRNAs (Figure 5f and g, Figure 5—figure supplement 1d and e). Likewise, MCF10A cells that overexpressed DNp53, were resistant to reverting agents (Figure 5h, Figure 5—figure supplement 1f).

**De novo synthesized LN5 is required for acinar morphogenesis**

It is known that the basement membrane (BM) of the mammary gland includes not only LN1 but also LN5. To maintain tissue architecture, signaling pathways need to regulate each other directly or indirectly (Bissell et al., 1982, 2005). We had shown previously that even after placing cells in lrECM, formation of acini and production of milk proteins still required an endogenously formed BM (Streuli and Bissell, 1990). Accordingly, we measured the levels of human LNs in the conditioned media (CM) and in cell lysates of S1 and T4-2 cells grown in lrECM. Using a human-specific pan-LN

| Mature ID    | Fold regulation S1 vs T4-2 | Fold regulation T4 rev vs T4 | P value |
|--------------|-----------------------------|-----------------------------|---------|
| miR-450b-5p  | 30.3789                     | 869.8262                    | 0.049943|
| miR-105      | 11.1967                     | 783.9313                    | 0.007486|
| miR-383      | 52.5275                     | 735.6709                    | 0.042511|
| miR-432      | 17.7736                     | 541.6623                    | 0.020574|
| miR-495      | 455.6135                    | 510.0813                    | 0.004495|
| miR-30e      | 65.4581                     | 228.7297                    | 0.047957|
| miR-190      | 48.2236                     | 221.0022                    | 0.044772|
| miR-369–3 p  | 14.1069                     | 158.4536                    | 0.041128|
| miR-323–3 p  | 13.8486                     | 118.1588                    | 0.015214|
| miR-127–5 p  | 10.5195                     | 115.9948                    | 0.005194|
| miR-330–3 p  | 39.2603                     | 113.8705                    | 0.044612|
| miR-382      | 24.6754                     | 82.0207                     | 0.021385|
| miR-337–3 p  | 36.2104                     | 35.2915                     | 0.003663|
| miR-423–3 p  | 55.2984                     | 32.9948                     | 0.045694|
| miR-125b     | 48.925                      | 29.9434                     | 0.04939 |
| miR-376a     | 212.9199                    | 11.2032                     | 0.049943|
| miR-296–5 p  | 42.5671                     | 8.5618                      | 0.045775|
| miR-135a     | 60.0253                     | 7.5379                      | 0.045617|
| miR-144      | 1234.0342                   | 7.3743                      | 0.003973|
| miR-301b     | 32.1668                     | 7.1892                      | 0.043739|
| miR-376c     | 49.8377                     | 6.2803                      | 0.046834|
| miR-487a     | 68.5143                     | 6.2243                      | 0.035722|
| miR-590–3 p  | 14.4952                     | 5.9622                      | 0.035266|
| miR-301a     | 30.8564                     | 5.4045                      | 0.047854|
| miR-98       | 33.6103                     | 5.1012                      | 0.041169|
| miR-34c–5p   | 31.215                      | 4.8038                      | 0.043702|
| miR-496      | 42.8632                     | 3.2108                      | 0.044913|
| miR-543      | 74.4569                     | 2.897                       | 0.01967 |
| miR-143      | 590.5164                    | 2.2076                      | 0.042274|
| miR-374a     | 11.1001                     | 1.1926                      | 0.013047|

DOI: https://doi.org/10.7554/eLife.26148.008
Figure 2. Restoring the expression of miR-34c-5p, –30e or –144 in breast cancer cells induces phenotypic reversion. (a) Actual expression pattern of the ten identified miRNAs (Figure 1): the levels are at least two-fold higher in S1 and T4-2 Rev cells than in T4-2 cells, as measured by northern analysis. 28S and 18S RNAs were used as internal controls. Fold difference was determined with respect to S1 cells. *p<0.05; **p<0.01; and ***p<0.001. (b) In situ hybridization of primary human breast tissues showed the abundance of miR-34c-5p, –30e and –144 in normal (top row) compared to tumor

Figure 2 continued on next page
antibody, we observed a significant increase in human LNs in both CM and lysates of S1 and T4-2 Rev cells reverted by expression of miRNAs or depletion of the two target genes (Figure 6—figure supplement 1a).

Functional LN proteins are heterotrimers of αβγ chains (Miner and Yurchenco, 2004). To determine which LN trimers were upregulated, we analyzed the CM of cells grown in lrECM cultures using antibody arrays against human ECM proteins. The α3, β3 and γ2 chains of LN5 were highly elevated in S1 and T4-2 Rev cells that expressed the miRNAs or that were depleted of their two targets. By contrast, parental T4-2 cells did not produce LN5, suggesting that LN5 is only expressed in MECs capable of forming acinar-like polarized structures (Figure 6—figure supplement 1b–d). To test the possibility, we depleted one of the LN5 subunits, LAMA3, with shRNA. Loss of LAMA3 abrogated reversion of T4-2 cells with any of the different reverting agents including any of the three miRNAs (Figure 6a and b, Figure 6—figure supplement 2a, b). Depletion of LAMA3 could be rescued by addition of ectopic LN5, confirming the specificity of the reaction (Figure 6a and b, Figure 6—figure supplement 2a and b).

To follow how LN5 was elevated in acinar formation and tumor cell reversion, we postulated that it could be due to LN5 protein stabilization due to suppression of MMP-9 transcription. We previously had shown that MMP-9, a metalloproteinase secreted to degrade LNs, is elevated in T4-2, but downmodulated in T4-2 Rev cells, leading to stabilization of secreted LNs (Beliveau et al., 2010).

Table 3. List of 12 miRNAs that were upregulated in S1 and T4-2 revertants and downmodulated in T4-2, and that could target more than 10 genes among the 60 genes that showed the opposite expression patterns.

| Mature ID     | Fold regulation T4 vs Control | Fold regulation T4 Rev vs T4 | p-value | # Targets / 60 genes | Gene locus | Type       |
|---------------|-------------------------------|-------------------------------|---------|----------------------|------------|------------|
| miR-450b-5p   | -30.3789                      | 869.8262                      | 0.000304| 15                   | Xq26.3     | Intergenic |
| miR-495       | -455.6135                     | 510.0813                      | 0.028964| 12                   | 14q32.31   | Intergenic |
| miR-30e*      | -65.4581                      | 228.7297                      | 0.008983| 11                   | 1p34.2     | Intergenic |
| miR-330–3 p   | -39.2603                      | 113.8705                      | 0.007481| 22                   | 19q13.32   | Intergenic |
| miR-382       | -24.6754                      | 82.0207                       | 0.001901| 12                   | 14q32.31   | Intergenic |
| miR-423–3 p   | -55.2984                      | 32.9948                       | 0.011304| 14                   | 17q11.2    | Intergenic |
| miR-135a      | -60.0253                      | 7.5379                        | 0.039409| 13                   | 3p21.1     | Intergenic |
|               |                               |                               |         |                      | 12q23.1    | Intergenic |
| miR-144*      | -1234.0342                    | 7.3743                        | 0.010599| 12                   | 17q11.2    | Down (p<0.05) |
| miR-301b      | -32.1668                      | 7.1892                        | 0.028553| 16                   | 22q11.21   | Intergenic |
| miR-590–3 p   | -14.4952                      | 5.9622                        | 0.043351| 21                   | 7q11.23    | Intergenic |
| miR-301a      | -30.8564                      | 5.4045                        | 0.044539| 13                   | 17q22      | Intergenic |
| miR-34c-5p*   | -31.215                       | 4.8038                        | 0.01567 | 10                   | 11q23.1    | Down (0 < 0.05) |

*The three miRNAs in bold that were the focus of this study.
†p-values were obtained from the array results [GSE2564] (Petersen et al., 1998).

DOI: https://doi.org/10.7554/eLife.26148.009
We measured the level of secreted MMP-9 in lrECM cultures and showed that MMP-9 was significantly reduced in T4-2 cells that expressed any of the three miRNAs- or were depleted of the two target genes, EIF5A2 and SCA1 (Figure 6c). It had been shown previously that both EIF5A2 and SCA1 lie downstream of the PI3K/AKT pathway and are involved in positive regulation of MMP transcription (Liu et al., 2000; Park et al., 2013; Khosravi et al., 2014). We concluded that expression of the miRNAs inactivates both EIF5A2 and SCA1 and thus downmodulates MMP-9 leading to stabilization of LN5.

Table 4. List of genes targeted by miR-34c-5p, miR-30e and miR-144 among the cluster of 60 genes that were downmodulated in S1 and T4-2 revertants and upregulated in T4-2.

| miR-144 (12 targets) | miR-30e (11 targets) | mir-34c-5p (10 targets) |
|----------------------|----------------------|------------------------|
| EIF5A2               | EIF5A2               | EIF5A2                 |
| EREG                 | EREG                 |                        |
| ERO1L                | ERO1L                |                        |
| FGD6                 | ISG20                |                        |
| KIAA1622             | NK4                  |                        |
| L1CAM                | L1CAM                |                        |
| PTBP1                | PTGS2                |                        |
| PTGS2                | RDBP                 |                        |
| SCA1 (ATXN1)         | SCA1 (ATXN1)         | SCA1 (ATXN1)           |
| SIAH2                | SIAH2                |                        |
| SLC2A14              | SLC2A3               |                        |
| SLC2A3               | SNX10                |                        |
| SS18                 | SS18                 |                        |
| TIMP2                |                      |                        |

DOI: https://doi.org/10.7554/eLife.26148.013

p53 activation during acinar formation is triggered by LN-induced nitric oxide (NO) production

We searched for possible explanations of how LNs activate p53. In older literature, LN was reported to induce NO production in neuronal and endothelial cells as part of mechanotransduction pathways (Gloe and Pohl, 2002; Rialas et al., 2000). As NO is reported to be a potent activator of p53 (Forrester et al., 1996; Wang et al., 2002), we hypothesized that LNs might also be instrumental in inducing NO production in breast cells, which in turn would activate p53. We applied purified LN5 (Figure 7a) or lrECM (Figure 7—figure supplement 1a) to MCF10A cells and observed an increase in pSer20-p53 after 30 min, along with increases in Ser1981-phosphorylated ATM and total level of p14 ARF, the known p53 activators (Canman et al., 1998; Zhang et al., 1998). Under the same conditions, Ser1417 phosphorylation of nitric oxide synthase 1 (NOS-1) was also elevated (Figure 7a, Figure 7—figure supplement 1a), suggesting its role in NO production. In contrast, DNp53 overexpressed in MCF10A cells was not activated in response to LNs, whereas ATM, p14 ARF and NOS-1 were all activated (Figure 7a, Figure 7—figure supplement 1a). When MCF10A cells were treated...
Figure 3. Dissection of miRNA target genes and promoter regulation. (a) Representative result of semi-quantitative RT-PCR (n = 3) to determine the levels of EIF5A2 and SCA1 in S1, T4-2 and T4-2 Rev cells (treated with AG1478). Fold difference was determined with respect to the Ctrl T4-2. *p<0.05 and **p<0.01 (b) T4-2 cells depleted of EIF5A2 or SCA1 grown in IrECM. (Top) Phase images overlaid with FITC to indicate transduced cells. (Bottom) Red — integrin α6 (red); blue — DAPI. Scale bars: 20 μm. See quantification in Figure 3—figure supplement 1b. (c) Activities of different miRNA promoters (n = 3) in S1, T4-2 and T4-2 Rev cells using the promoter constructs shown in Figure 3—figure supplement 2a. Note that a 1–0 kb fragment of miR-34c promoter, a 3–0 kb fragment of miR-30e promoter and a 3–0 kb fragment of miR-144 promoter were activated in the S1 and T4-2 Rev cells. (d) Activities of different miRNA promoters (n = 3) in S1, T4-2 and T4-2 Rev cells using the promoter constructs shown in Figure 3—figure supplement 2b. Note that a 1–0 kb fragment of miR-34c promoter, a 3–2 kb fragment of miR-30e promoter and a 3–2 kb fragment of miR-144 promoter were activated in S1 and T4-2 Rev cells. Data are represented as mean ± SEM. For each analysis, replicate experiments (n = 3) were performed, and representative data are shown.

DOI: https://doi.org/10.7554/eLife.26148.010

The following figure supplements are available for figure 3:

Figure supplement 1. Identification of the downstream targets of the three miRNAs and generation of the promoter constructs of the miRNA genes.

DOI: https://doi.org/10.7554/eLife.26148.011

Figure supplement 2. Scheme of reporter constructs derived from the promoter regions of the three miRNAs genes.

Figure 3 continued on next page
with a NOS inhibitor, L-NAME, that inhibits NO production, LN5-mediated activation of p53, as well as of ATM and p14 ARF, were severely impaired (Figure 7b).

We measured the level of NO in CM after addition of LN5s using a fluorescence probe, DAN, against NO metabolites. S1 and MCF10A cells produced NO as a function of time in response to LN5 or IrECM (Figure 7c and d). By contrast, T4-2 cells failed to do so (Figure 7c and d). Addition of another ECM protein collagen-1 (COL1) did not induce NO production by S1 or MCF10A cells (Figure 7e), suggesting a unique role of LN5s. We then monitored the intracellular NO level after addition of IrECM using a fluorescence probe DAF-FM DA. NO level peaked at around 1 hr after IrECM addition and declined thereafter in S1 and MCF10A cells, whereas it remained low in T4-2 cells (Figure 7f, Figure 7—figure supplement 1b).

To confirm the biological relevance of NO production by MECs, we stained 3D colonies for S-nitrosocysteine (SNOC), an indicator of NO production (Gould et al., 2013) and localization (Iwakiri et al., 2006). S1 acini showed strong basolateral SNOC staining, whereas T4-2 cells showed weak and dispersed staining. However, T4-2 Rev cells restored the strong basolateral SNOC staining analogous to S1, suggesting the recovery of NO production upon phenotypic reversion (Figure 7g, Figure 7—figure supplement 1c). We then stained normal (n = 8) vs. cancerous (n = 32) breast tissue sections for SNOC. Normal mammary epithelia were distinctively stained for SNOC, whereas the majority of tumor samples were only weakly and diffusely stained [positive staining (intensity >+1): 8/8 vs. 8/32, respectively] (Figure 7h). These results support the relevance of NO production to the biology of the normal breast.

**NO is critical for mammary acinar formation and gland morphogenesis**

NO is known to play a role in the differentiation and morphogenesis of neurons, muscles and immune cells (Rialas et al., 2000; Stamler and Meissner, 2001; Niedbala et al., 2002). To test the involvement of NO in mammary morphogenesis, we inhibited NO production with L-NAME in two different non-malignant breast epithelial cells; this led to the formation of disorganized proliferative structures in IrECM (Figure 8a and b, Figure 8—figure supplement 1a and b). Alternatively, the induction of NO production in T4-2 cells with a NO donor, SNAP, induced phenotypic reversion (Figure 8c, Figure 8—figure supplement 1c). Also, application of L-NAME to T4-2 cells, even in the presence of a reverting agent (e.g., an inhibitor of EGFR or β1 integrin) (Bissell et al., 2003), abrogated phenotypic reversion in IrECM (data not shown). To determine whether the activity of NO is necessary for human mammary gland morphogenesis, we monitored the alveologenesis of breast organoids treated with L-NAME in ex vivo 3D cultures. L-NAME treatment dramatically reduced the percentage of colonies capable of alveologenesis (vehicle-treated: 28% vs. L-NAME-treated: 1.2%) (Figure 8d, Videos 1 and 2).

We tracked movement of LNAME-treated S1 cells in IrECM for 48 hr by live cell imaging. We and others have shown previously that acinar forming non-malignant breast cells undergo CAMo in

| miRNA      | Seed      | miRNA binding site in 3’ UTR of mRNA |
|------------|-----------|-------------------------------------|
| SCA1       | GGCAGUG   | 691, 913, 6461                       |
| hsa-miR-34c| GGCAGUG   | 691, 913, 6461                       |
| hsa-miR-30e| GUAAACA   | 3588, 4308, 4603, 4770, 5440, 6092, 6233 |
| hsa-miR-144| GAUAUCA   | 47, 987, 1113, 1160, 4557, 5426, 6267 |
| EIF5A2     | GGUUS     | 297, 802, 2656                       |
| hsa-miR-34c| GGCAGUG   | 297, 802, 2656                       |
| hsa-miR-30e| GUAAACA   | 3264, 3312, 3525, 3652, 3643, 4113   |
| hsa-miR-144| GAUAUCA   | 2642, 2742, 2977, 4123, 4541, 4570   |

DOI: https://doi.org/10.7554/eLife.26148.014
Table 6. miRNA promoter regions harboring binding sites of TFs, NFκB (p65) and HOXD10.

| miRNA promoter | TXN bound | Start nt from TSS | End nt from TSS | String             | Dissimilarity (%) | Equally | Query |
|----------------|-----------|-------------------|-----------------|--------------------|-------------------|---------|-------|
| miR-34c        | RelA      | −787              | −778            | AGGGAATCAA         | 14                | 1 \times 10^{-5} | 1 \times 10^{-5} |
|                |           | −769              | −760            | TGGGAAGTTT         | 11                | 3 \times 10^{-5} | 5 \times 10^{-5} |
|                |           | −427              | −418            | TGGGAACCTT         | 11                | 4 \times 10^{-5} | 3 \times 10^{-5} |
|                |           | −64               | −55             | TGGGAAGCCG         | 13                | 4 \times 10^{-5} | 4 \times 10^{-5} |
|                |           | −56               | −47             | CGCTTTCCCA         | 12                | 5 \times 10^{-5} | 4 \times 10^{-5} |
|                |           | −3                | 6               | GGGAATGAGG         | 13                | 3 \times 10^{-5} | 3 \times 10^{-5} |
| HOXD10         |           | −864              | −855            | AGTTTGTATT         | 10                | 1 \times 10^{-4} | 2 \times 10^{-4} |
|                |           | −385              | −376            | CCCTTCTATT         | 12                | 3 \times 10^{-5} | 4 \times 10^{-5} |
| miR-30e        | RelA      | −2888             | −2879           | GATATTCCCA         | 2                 | 6 \times 10^{-6} | 5 \times 10^{-6} |
|                |           | −2553             | −2544           | TGTTTGTATT         | 10                | 1 \times 10^{-4} | 2 \times 10^{-4} |
|                |           | −2230             | −2221           | GCGTGTATT          | 11                | 1 \times 10^{-4} | 1 \times 10^{-4} |
|                |           | −2122             | −2113           | TTTTTTATT          | 4                 | 1 \times 10^{-5} | 4 \times 10^{-5} |
|                |           | −1967             | −1967           | TACTCATATT         | 9                 | 1 \times 10^{-4} | 2 \times 10^{-4} |
| miR-144        | RelA      | −3207             | −3198           | AGGGAAATTG         | 10                | 5 \times 10^{-5} | 5 \times 10^{-5} |
|                |           | −2850             | −2841           | AATAGAATGA         | 10                | 1 \times 10^{-4} | 2 \times 10^{-4} |
|                |           | −2715             | −2706           | AATACAAAAA         | 10                | 1 \times 10^{-4} | 2 \times 10^{-4} |
|                |           | −2412             | −2403           | CCATATTATT         | 11                | 1 \times 10^{-4} | 1 \times 10^{-4} |
|                |           | −2336             | −2327           | AATAAGAGTA         | 7                 | 5 \times 10^{-5} | 7 \times 10^{-5} |
|                |           | −2312             | −2303           | ATTATTATTATT       | 10                | 1 \times 10^{-4} | 2 \times 10^{-4} |

DOI: https://doi.org/10.7554/eLife.26148.017

IrECM, whereas cancer cells exhibit random amoeboid motion (Tanner et al., 2012; Wang et al., 2013). S1 cells treated with L-NAME are defective in CAMo and form disorganized masses (Figure 8e, Videos 3 and 4).

**LN5 activates p53 phosphorylation and p53 activates LN5 transcription**

We showed above that NO production in response to IrECM is critical for p53 activation and the formation of mammary acini (Figures 7a–g and 8a–e). This process involves de novo synthesized LN5 (Figure 6a and b). We also showed that p53 upregulates the expression of HOXD10 and downregulates activation of NFκB. This dual action allows expression of the three miRNAs that inhibit TFs, SCAI and EIF5A2, to downmodulate MMP-9 expression. The result is inhibition of laminin protein degradation, leading to the closure of the morphogenetic loop (Figure 9a).

To demonstrate reciprocity in 3D, we selected the interaction between p53 and LN5, where a single manipulation at any part of the cycle allowed integration of all the pathways examined, PROMO analysis of the promoter of LAMA3 chain of LN5 revealed over 20 high-confidence p53 binding sites within 1 kb length of the CpG island around the transcription start site (% dissimilarity <8%; genomic frequency <1 \times 10^{-3}) (Figure 9b, Table 8) (Farré et al., 2003). Consistently, LAMA3 expression in S1 cells, could be abrogated by p53 inhibition with α-pifithrin (Figure 9c, Figure 9—figure supplement 1a), whereas ectopic addition of LN5 or IrECM, elevated LAMA3 transcription (Figure 9d, Figure 9—figure supplement 1b) in parallel to the activation of wild-type p53 (Figure 7a, Figure 7—figure supplement 1a).

To see whether there is a correlation between the wild-type p53 and LAMA3 levels in vivo, we performed immunohistochemical analyses of primary breast tissues using antibodies against the wildtype p53 (Clone pAb1620) and LAMA3 (Clone 546215). All normal breast tissue sections were stained strongly with both antibodies (Figure 9—figure supplement 1c). The reciprocity between LN5 and wild-type p53 remains strong even as cells progress to malignancy. The levels of the two proteins fell in parallel in the tumor samples (R = 0.51, p<0.0001, n = 117) (Figure 9e).
The essential and prominent steps of the acinar circuitry are shown in the schematic presented in Figure 10.

Discussion
The ability to phenotypically revert breast cancer cells by inhibiting a single signaling pathway in 3D lrECM has provided us with the means to identify additional major signaling pathways that must...
| miRNA promoter | TXN bound | Start from TSS | End from TSS | Predicted binding sequence | Wt decoy sequence (5′ → 3′) | Mt decoy sequence (5′ → 3′) | Transfected T4-2 cells |
|----------------|------------|----------------|--------------|----------------------------|-----------------------------|-----------------------------|--------------------------|
| Scramble       |            |                |              |                            | TTCCGTCATCTGACTTACC         |                            |                          |
| miR-34c NFκB   | −787       | −778           |              |                            | AGGGGAATCAA                 |                            | Ctrl (pDCF1)             |
| miR-34c NFκB   | −769       | −760           |              |                            | TGGAAGATTT                |                            | Ctrl (pDCF1)             |
| miR-34c NFκB   | −427       | −418           |              |                            | TGGAACCTT                |                            | Ctrl (pDCF1)             |
| miR-34c NFκB   | −64        | −55            |              |                            | TGGAAGCCG                 |                            | Ctrl (pDCF1)             |
| miR-34c NFκB   | −56        | −47            |              |                            | CGCTTTCCCA                |                            | Ctrl (pDCF1)             |
| miR-34c NFκB   | −3         | 6              |              |                            | GGGGAATGAG                |                            | HOXD10/ pDCF1            |
| miR-30e NFκB   | −2888      | −2879          |              |                            | GATATTCCCA                |                            | Ctrl (pDCF1)             |
| miR-30e NFκB   | −385       | −376           |              |                            | CCGCATTT                  |                            | Ctrl (pDCF1)             |
| miR-30e NFκB   | −2230      | −2221          |              |                            | GCCTGATATT                |                            | Ctrl (pDCF1)             |
| miR-30e NFκB   | −2122      | −2113          |              |                            | TTTTTTATT                  |                            | Ctrl (pDCF1)             |
| miR-30e NFκB   | −1967      | −1967          |              |                            | TACTCATATT                 |                            | Ctrl (pDCF1)             |
| miR-144 NFκB   | −3207      | −3198          |              |                            | AGGGAAATTG                 |                            | Ctrl (pDCF1)             |
| miR-144 NFκB   | −2715      | −2706          |              |                            | AATACAAAAA                |                            | Ctrl (pDCF1)             |
| miR-144 NFκB   | −2412      | −2403          |              |                            | CCATATTAT                  |                            | Ctrl (pDCF1)             |

Table 7 continued on next page
integrate for the formation of ‘phenotypically normal’ human breast acini (Weaver et al., 1997; Muschler et al., 2002; Beliveau et al., 2010; Bissell and Hines, 2011; Lee et al., 2012; Tanner et al., 2012; Becker-Weimann et al., 2013). Here, we set out to develop a blueprint for how the breast cells interpret their interactions with the ECM proteins LN1 and LN5. The LNs trigger the signaling cascade leading to reciprocal communications between the ECM and TFs essential for mammary morphogenesis.

To do this, we used a unique breast cancer progression series, HMT3522: non-malignant S1, malignant T4-2 and T4-2 reverted to non-malignant phenotype (using five signaling inhibitors of oncogenic pathways, where addition of single inhibitors could revert the malignant phenotype). We observed that, although T4-2 Rev cells have similar phenotypes, their gene expression patterns were very different (Becker-Weimann et al., 2013). Nevertheless, a comparison of the gene arrays of the five T4-2 revertants identified a group of 60 similar genes that are also expressed in S1 cells (Figure 1d) (Becker-Weimann et al., 2013). This led us to propose that the common denominator of reversion had to contain a number of miRNAs that regulate this gene subset. We thus devised miRNA expression arrays and identified 10 miRNAs that fit the above category (Figure 2a). This result, together with the literature search (Lu et al., 2005) and our analysis of miRNA expression in normal- vs. cancerous- breast tissues (Figure 2b), identified three miRNAs (miR-34c-5p, hsaC030e, and hsaC0144) that were shown to be severely downmodulated in primary breast tumors (Figure 2b and c, Figure 2—figure supplement 1) (Lu et al., 2005). As expected, restoration of any of these three miRNAs in T4-2 cells led to phenotypic reversion in lrECM (Figure 2e). We utilized these miRNAs as the focal starting point to dissect the fundamental reciprocal pathways necessary for the formation and maintenance of breast tissue architecture.

It has been long known that diverse biological activities in development are regulated by tissue–tissue and tissue–microenvironment interactions and signaling (Wessells, 1977; Chiquet-Ehrismann et al., 1986; Howlett and Bissell, 1993; Hogan, 1999; Bhat and Bissell, 2014). During development, different cell types communicate and coordinate with each other through negative and positive feedback regulations. Within a given tissue, there are also negative and positive operators that must be regulated constantly to maintain homeostasis and quiescence as we demonstrated here. In addition, similar to movements that are being discovered in the formation of embryos during development (Haigo and Bilder, 2011), tissue formation starts with cells moving within a soft microenvironment such as lrECM, as we and others observed for mammary acini; we termed this ‘coherent angular motion’ (Tanner et al., 2012). CAMo creates polarity and adhesion by interacting with exogenous ECM to lay down its own endogenous tissue-specific ECM (Tanner et al., 2012).

The balance and integration of the different signaling pathways and dynamic interactions between epithelial cells and the ECM drive the remodeling of the ECM, including formation of the BM that helps to anchor the epithelia (Weaver et al., 2002) and that protects the cells within the tissues from apoptosis. Such changes in the ECM regulate cell proliferation, survival, migration, shape and adhesion, ultimately sculpting and maintaining tissue architecture (Wessells, 1977; Chiquet-Ehrismann et al., 1986; Howlett and Bissell, 1993; Hogan, 1999; Bhat and Bissell, 2014; Haigo and Bilder, 2011; Weaver et al., 2002; Daley and Yamada, 2013). There are important

Furuta et al. eLife 2018;7:e26148. DOI: https://doi.org/10.7554/eLife.26148

Table 7 continued

| miRNA promoter | TXN bound | Start from TSS | End from TSS | Predicted binding sequence | Wt decoy sequence (5’ → 3’) | Mt decoy sequence (5’ → 3’) | Transfected T4-2 cells |
|----------------|-----------|----------------|-------------|---------------------------|-----------------------------|---------------------------|------------------------|
| −2336          | −2327     | AATAAGAGTA     | TSS         | F CTTGAAAATAAGAGTATCC     | F CTTGAAAACAcTATATTtCC     | HOXD10/ pCDF1             |
|                |           |                |             | R GGAcAgAcTcAcTtCTAAGG    | R GGAcAgAcTcAcTtCTAAGG     | HOXD10/ pCDF1             |
| −2312          | −2303     | ATTTATTATT     | TSS         | F CTTGAAAATTATTTATTTC     | F CTTGAAAAGcTggGTTTtCC     | HOXD10/ pCDF1             |
|                |           |                |             | R GGAAcAgAcTcAcTtCTAAGG   | R GGAAcAgAcTcAcTtCTAAGG   | HOXD10/ pCDF1             |

Note: the transcription factor binding sites are underlined, whereas mutated nucleotides are indicated in lower case.
DOI: https://doi.org/10.7554/eLife.26148.018
Figure 5. p53 activation is another requirement for tumor-cell reversion by the miRNAs. (a) Representative result of western analysis (n = 3) for the level and activation of proteins in the p53 pathway [p53 (p-Ser20), DRAM, p21 and GADD45] in S1, T4-2 and T4-2 Rev cells. T4-2 Rev cells include those treated with AG1478, those expressing the three miRNAs and those depleted of the two target genes (EIF5A2 and SCA1). Fold difference was determined with respect to S1 cells. *p<0.05 and **p<0.01. (b) Representative result of western analysis (n = 3) for the activities of HOXD10 and p65 (p-p65) in Ctrl S1 cells and in S1 cells that were overexpressing the wild-type (wt) or dominant-negative mutant (DN) p53. Note the opposing effects of wtp53 or DNp53 expression on HOXD10 vs.
p-p65. Fold difference was determined with respect to Ctrl S1. *p<0.05 and **p<0.01. (c) Representative image for S1 cells overexpressing wtp53 (top) or DNp53 (bottom) grown in IrECM. Ctrl S1 cells were un-transduced. See the quantification of 3D colony size in Figure 5—figure supplement 1a. (d) Representative image for Ctrl S1 (top) and S1 cells depleted of p53 (bottom) grown in IrECM. Red — α6, green — apical marker GM130. See the confirmation of p53 depletion and quantification of the 3D colony size in Figure 5—figure supplement 1b. (e) Representative image for Ctrl MCF10A cells (top) and MCF10A cells depleted of p53 (bottom) grown in IrECM. See the confirmation of p53 depletion and quantification of the 3D colony size in Figure 5—figure supplement 1c. (f) Representative image of 3D morphologies of T4-2 cells co-treated with a reverting agent [AG1478 (EGFR inhibitor), LY294002 (PI3K inhibitor) or PD98059 (MEK inhibitor)] along with p53 inhibitor α-pifithrin (α-PFT). Note that α-PFT treatment abrogated reversion of T4-2 cells. See the quantification of 3D colony size in Figure 5—figure supplement 1d. (g) Representative image of 3D morphologies of miRNA-overexpressing T4-2 cells co-treated with a reverting agent [AG1478 (EGFR inhibitor), LY294002 (PI3K inhibitor) or PD98059 (MEK inhibitor)] along with p53 inhibitor α-pifithrin (α-PFT). Note that α-PFT treatment abrogated the reversion of T4-2 cells after expressing miRNAs. See the quantification of the 3D colony size in Figure 5—figure supplement 1e. (h) Representative image of 3D morphologies of DNp53-expressing MCF10A cells treated with a reverting agent [AG1478 (EGFR inhibitor), LY294002 (PI3K inhibitor) or PD98059 (MEK inhibitor)]. Note that DNp53-expressing cells are more proliferative, fail to form acini and are resistant to a reverting agent. See the quantification of the 3D colony size in Figure 5—figure supplement 1f. Red — integrin α6; green — Golgi marker, GM130; and blue — DAPI. Scale bars: 20 μm. For each analysis, replicate experiments (n = 3) were performed, and representative data are shown.

DOI: https://doi.org/10.7554/eLife.26148.019

The following figure supplement is available for figure 5:

Figure supplement 1. p53 activation is essential for acinar formation and tumor-cell reversion.

DOI: https://doi.org/10.7554/eLife.26148.020

differences, however, between developmental processes and tissue maintenance and renewal (Howlett and Bissell, 1993; Hogan, 1999; Bhat and Bissell, 2014; Daley and Yamada, 2013). Unlike the signaling pathways in development, the stability of the differentiated state does not appear to be hierarchical. Instead, it reflects the balance between growth and differentiation, between the negative and positive signaling pathways, and between the formation of a BM and the destruction of ECM by degrading enzymes that determines the stability of the differentiated state in the tissues.

Another novel finding here is that NO is a pivotal player in reciprocal cell–ECM interactions in breast morphogenesis, but tumor cells produce only a small amount of NO unless the architecture is re-established and the cells have reverted to a ‘dormant state’ (Figure 7c–e and g). This is a mimicry of differentiation-dependent tissue architecture. These findings demonstrate that NO production is a mechanistic link between proper architecture and proper function in breast tissues. Please see also the accompanying paper of Ricca et al., 2018, which describes how the reversion of T4-2 cells induced by a short period of compression in laminin is also mediated by NO production.

There are a few papers in the literature on connections between LN1 and NO in other tissues (Rialas et al., 2000; Gloe et al., 1999), and there are other reports of activation of p53 by high levels of exogenous NO (Forrester et al., 1996; Gordon et al., 2001; Wang et al., 2003). To our knowledge, however, there are no reports of endogenous NO as a critical link in the formation of mammary epithelium and its role in stability of the tissue architecture.

It is crucial to note that the levels of NO produced endogenously in response to LN1s in our studies, as well as the exogenous NO levels required for the reciprocal loop we describe here, are at least 500-fold lower than those used in the literature (Forrester et al., 1996; Gloe et al., 1999; Gordon et al., 2001). As stated long ago, differences in quantity of such magnitudes becomes a change in quality and hence have appreciable consequence (Bissell, 1981).

NO has been reported to play an important role during lactation. Increased levels of NO are produced by the mammary gland of postpartum mammals (Akçay et al., 2002). NO promotes blood flow and the nutrient uptake of mammary glands for milk production (Kim and Wu, 2009). NO is also proposed to facilitate milk ejection by inducing contraction of myoepithelial cells (MEPs) in mammary glands as well as smooth muscle cells in the stroma (Iizuka et al., 1998; Adríance et al., 2005; Tezer et al., 2012). In addition, NO is secreted into the breast milk as an essential component...
Figure 6. MMP-9 degrades LN5 and prevents tumor-cell reversion, miRNAs’ ability to revert T4-2 cells is connected to inhibition of MMP-9 and the rescue of LN5. (a) Representative images of replicate experiments (n = 3) of 3D morphologies of T4-2 cells (vector, LAMA3sh, LAMA3sh + LN5) reverted with a reverting agent, AG1478, LY294002 or PD98059. See the quantification of the 3D colony size in Figure 6—figure supplement 2a. Note that the depletion of LAMA3 abrogated the reverting effect, which was rescued by ectopic addition of LN5 (1 μg/ml). Red — α6 integrin; blue — DAPI. Scale bars: 20 μm. (b) Representative images of replicate experiments (n = 3) of 3D morphologies of T4-2 cells (vector, LAMA3sh, LAMA3sh + LN5) overexpressing individual miRNAs. See the quantification of the 3D colony size in Figure 6—figure supplement 2b. Note that the depletion of LAMA3 abrogated the reverting effect of the miRNAs, which was rescued by ectopic addition of LN5. (c) The mean MMP-9 level (n = 9) in the CM of T4-2 cells, T4-2 cells expressing one of the three miRNAs or T4-2 cells depleted of the two target genes, EIF5A2 and SCA1, was determined 24 hr after addition of rECM (5% Matrigel). The concentration of MMP-9 was determined using the MMP-9 standard. Data represented as mean ± SEM. **p<0.01 and ***p<0.001. DOI: https://doi.org/10.7554/eLife.26148.021

The following figure supplements are available for figure 6:

Figure 6 continued on next page
for immunity in neonatal growth (Hord et al., 2011). Using 3D cultures and ex vivo cultures of human mammary glands, we showed here that NO also plays additional and significant roles in breast morphogenesis (Figure 8a, b and d).

Importantly, NO production was specific to LNs and was not induced by collagen (Figure 7c-e). We and others had shown previously that LNs and COL1 elicit opposite actions on epithelia (Gudjonsson et al., 2002; Oktay et al., 2000; Chamoux et al., 2002). We showed here that LNs activate NOS-1 (Figure 7a, Figure 7—figure supplement 1a), supporting previous observations by others that NOS-1 is expressed in the mammary tissue at appreciable levels — in particular in MEPs during pregnancy and lactation in humans (Tezer et al., 2012) and rodents (Iizuka et al., 1998; Islam et al., 2009; Wockel et al., 2005). As the molecule that appears to be responsible for linking LNs to NOS-1, we speculate the involvement of the LN receptor, dystroglycan (DG), which is known to form a multi-protein complex involving LNs and NOS-1, in mediating the mechanotransduction of muscle cells (Rando, 2001; Garbincius and Michele, 2015). We had shown previously that DG also plays a critical signaling role in breast epithelial cells (Muschler et al., 2002). DG anchors the BM protein, in particular LNs, to the cell surface, allowing for LN polymerization and transduction of signals for the formation of polarized colonies (Weir et al., 2006). Such DG–LN interaction is impaired in different types of cancer cells and correlates with poorer patient prognosis (Akhavan et al., 2012; Esser et al., 2013).

Form and function are maintained in adult organs throughout most of the life of the organism, despite constant mutations and damage from environmental assaults and aging. To maintain the correct tissue function throughout the lifetime of the organisms, signaling pathways have to integrate in order to prevent chaos and malfunction. Evolution has packed much wisdom and specificity onto the ECM, which appears to instruct the chromatin to change shape and thus also gene expression, as seen in Figure 4e. When cells on flat surfaces receive LNs, not only their shape, but also many of their signaling pathways are altered (Figure 1) (Bissell et al., 2005); growth must stop in many tissues (Spencer et al., 2011; Fiore et al., 2017) and differentiation and cell death must be coordinated. It is now clear that narratives that are based solely on linear and irreversible regulatory dynamics cannot satisfactorily explain the reality in vivo (Hogan, 1999). It is also clear that, at the last analysis, it is the 3D architecture of the tissue itself that is the message (Hagios et al., 1998).

Materials and methods

Cell lines

Cell lines of the HMT3522 breast cancer progression series (S1 and T4-2) were provided by O.W. Petersen (Laboratory of Tumor Endocrinology, The Fibiger Institute, Copenhagen, Denmark) (Briand et al., 1996). The cell lines were authenticated by genome sequencing by the provider. Mycoplasma testing was negative. MCF10A cells were obtained from the Karmanos Cancer Institute (Detroit, MI, USA) under a Material Transfer Agreement. The cell lines was authenticated by the provider. Mycoplasma testing was negative.

Cell culture and reagents

The isogenic cell lines of the HMT3522 human breast cancer progression series, non-malignant S1 and malignant T4-2 cells, were maintained as described previously (Briand et al., 1996). This cell line series was established in an attempt to recapitulate the stochastic and prolonged nature of breast cancer progression by continuously culturing S1 cells, derived from reduction mammoplasty, in the absence of serum, followed by EGF removal and injection into mice, to give rise to T4-2 cells (Briand et al., 1996). For 3D culture experiments, S1 and T4-2 cells were seeded at the density of...
Figure 7. LNs activate p53 through production of NO. (a) Representative results of western analysis (n = 3) for MCF10A cells expressing either wtp53 or DNmtp53, showing the level of activated p53 (p-Ser20) after addition of exogenous LNS5 (1 μg/ml). Other lanes indicate the levels of p14 ARF and activation of ATM and NOS-1 after LN5 addition. Fold differences were determined first by normalization with respect to β-actin and then by normalization with respect to the value at time 0. *p<0.05; **p<0.01 and ***p<0.001. See similar results after the addition of Matrigel (5%) in Figure 7—Figure 7 continued on next page.
2.5 × 10^4 cells/cm^2 and 1.8 × 10^4 cells/cm^2, respectively, in growth factor reduced Matrigel (Corning, NY, USA) and maintained for 10 days with the addition of fresh medium on alternate days. For T4-2 reversion, EGFR inhibitor AG1478 (EMD Millipore, Burlington, MA, USA) was used at 350 nM, PI3K inhibitor LY294002 at 8 μM, and MEK inhibitor PD98059 at 20 μM (Lee et al., 2012). For p53 inhibition, 30 μM α-PFT (α-pifithrin, Sigma-Aldrich, St. Louis, MO, USA) was used. For inhibition of NO production, cells were treated with 2.5 mM L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride, Sigma- Aldrich); for induction of NO production, 10 μM SNAP (S-Nitroso-N-acetyl-DL-penicillamine, Sigma- Aldrich) was used.

**miRNA array**

miRNA expression profiling was performed using the RT^2 miRNA PCR Array System (Qiagen, Inc. USA, Germantown, MD, USA) on the MyiQ Single-Color Real-Time PCR platform (Bio-Rad, Hercules, CA, USA). Briefly, 1.0 × 10^6 cells were grown in 1.2 ml Matrigel in 30 mm-plates for 10 days (for T4-2 Rev, 350 nM AG1478 was added). The medium was removed and cells were scraped off from the dish with 2 ml phosphate-buffered saline (PBS) with 5 mM EDTA. Cells were spun down to harvest pellets, which were repetitively washed with ice-cold PBS + EDTA until the Matrigel was dissolved. The total RNA was extracted with 1 ml Trizol (Life Technologies) and purified with an RNeasy plus mini kit (Qiagen, Inc, USA) according to the manufacturer’s protocols. cDNA was generated from 4 μg of RNA using the RT^2 miRNA First Strand Kit (SABiosciences), mixed with SYBR Green Master Mix (SABiosciences) and loaded onto an array with 98 wells. Real-time PCR was performed according to the manufacturer’s instructions, and data analysis was performed using the manufacturer’s PCR Array Data Analysis Web Portal (Qiagen, Inc, USA).

**Northern analysis**

Northern analysis of miRNAs was performed using the DIG detection system from Roche. Briefly, 1.0 × 10^6 cells/30-mm plate were grown in 1.2 ml Matrigel in triplicates for 10 days (for T4-2 Rev, 350 nM AG1478 was added). Cells were scraped off from the dish with PBS with 5 mM EDTA, spun down and washed with PBS + EDTA until the Matrigel was dissolved. The total RNA was extracted with 1 ml Trizol (ThermoFisher Scientific, Waltham, MA, USA). 20 μg of RNA was separated by denaturing polyacrylamide TBE-Urea gel electrophoresis (ThermoFisher Scientific) and electroblotted onto Bright-Star nylon membrane (Ambion) with 0.5% TBE for 2 hr. The membrane was rinsed in 2xSSC buffer, UV cross-linked at 120 mJ/cm^2, dried and stored between filter papers. LNA-modified DNA oligonucleotides complementary to the mature miRNA sequences (Table 9) were obtained from IDT and DIG-labeled using the DIG Oligonucleotide Tailing Kit (Roche Diagnostics, USA, Indianapolis, IN, USA). Using DIG Easy Hyb (Roche Diagnostics, USA), the membrane was prehybridized and hybridized with DIG-labeled probe at room temperature overnight. The membrane was washed.
Figure 8. NO is involved critically in breast acinar formation and mammary gland morphogenesis. (a–b) Representative images (n = 3) of S1 (a) and MCF10A (b) cells grown in lrECM in the absence (vehicle only) or presence of an NO inhibitor, L-NAME (2.5 mM). Scale bars: 20 μm. (c) Representative image (n = 3) of T4-2 cells grown in lrECM in the absence (vehicle only) or presence of an NO donor, SNAP (10 μM). (a–c) (Left) Phase images. (Right) Cells stained for integrin α6 (red) and nuclei (blue). Scale bars: 20 μm. See the quantification of colony size in Figure 8—figure supplement 1a–c. (d) Representative images of ex vivo cultures of normal human mammary gland organoids grown in lrECM for 1 week. The numbers of organoids that underwent alveologenesis were 45 out of 162 vehicle-treated, and only 2 out of 170 L-NAME-treated organoids. (e) (Top) Representative result (n = 5) of tracking analysis for the movement of S1 cells during 48 hr of growth in lrECM in the absence (vehicle only) or presence of L-NAME. (Bottom) Representative image of the colonies (n = 5) formed by cells after respective treatments for 10 days. Red — integrin α6, blue — nucleus. Scale bars: 50 μm. Figure 8 continued on next page
in 10xSSC + 0.1% SDS four times and processed for DIG detection using the DIG Luminescent Detection Kit (Roche) according to the manufacturer’s protocol.

**miRNA in situ hybridization (ISH)**

miRNA in situ hybridization (ISH) was performed using the miRCURY LNA miRNA ISH Optimization kit for formalin-fixed paraffin embedded (FFPE) tissues (Qiagen, Inc, USA) and double-DIG-labeled detection probes for miR-34c-5p, miR-30e and miR-144 (EXIQON) on breast cancer tissue arrays containing paraffin-embedded sections of normal and malignant (stages II and III) tissues (US BioMax, Inc, Rockville, MD, USA). Briefly, the tissue slides were heated at 60°C for 1 hr, deparaffinized in xylene and hydrated in alcohol series (100% to 70%). Slides were deproteinated with proteinase K for 20 min, fixed in 4% paraformaldehyde for 10 min and washed with 0.2% glycine in PBS for 5 min. Then, slides were incubated in imidazole buffer (0.13 M 1-methylimidazole, 300 mM NaCl, pH 8.0) for 10 min twice, in EDC solution (0.16M 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide [EDC], pH 8.0) for 1.5 hr and washed with 0.2% glycine in PBS. Then, slides were dehydrated in an alcohol series (70% to 100%), hybridized with heat-denatured probes at room temperature overnight, and processed for DIG detection according to the manufacturer’s protocol (Qiagen, Inc, USA). The slides were counterstained with Nuclear Fast Red and mounted with permount. Photomicrographs were taken with the Zeiss Axioskop Imaging Platform and Axion Vision software (Version 4.7).

**miRNA expression constructs**

Lentivector-based precursor constructs for miR-34c-5p, miR-30e and miR-144 co-expressing copGFP were obtained from System Biosciences Palo Alto, CA, USA, and the virus particles to express each miRNA were produced according to the manufacturer’s guideline.

**Gene-overexpressing lentiviral constructs**

For construction of HOXD10-overexpressing lentivirus, the full-length human HOXD10 cDNA clone was obtained from Open Biosystems (Lafayette, CO, USA, Clone ID: 7262455). For construction of p53-overexpressing lentivirus, both wild-type and dominant-negative (A135V) p53 expression plasmids were obtained from Clontech. The coding region was PCR-amplified using the respective primers (Table 9). The PCR product was ligated into the Ascl/EcoR1 site (for HOXD10) or the BamHI/EcoR1 site (for p53) of the PCDF1-MCS2-EF1-puro lentiviral vector (System Biosciences). For the SCA1- and EIF5A2-overexpression lentivirus construct, the cDNA clones were obtained from OriGene (Rockville, MD, USA, Cat#RC222862 and Cat#RC206249, respectively) and cloned into PCDF1-MCS2-EF1-puro lentiviral vector at the BamHI/EcoR1 site using the Gibson assembly system and a DNA assembly kit (Cat# E5520S, NEB) with the primers designed on the NEB Builder Assembly Tool website as shown in Table 9.

**Gene knockdown by shRNA**

For shRNA production, a double-stranded DNA oligonucleotide was generated from the respective sequences (Table 9). Sense and antisense oligonucleotides were annealed and ligated into BamHI/EcoR1 site of pGreen puro lentiviral vector which co-expresses copGFP (System Biosciences).

**Lentivirus production and transduction**

Lentivirus production and transduction of target cells were conducted following the guideline by System Biosciences. Briefly, lentivirus vector and packaging plasmid mix (System Biosciences) were transfected into 293FT cells (ThermoFisher Scientific) using Lipofectamine 2000. After 48 hr, medium...
was harvested, filtered and used to infect target cells with the addition of polybrene (10 μg/ml). The medium was replaced after 24 hr. At 72 hr post-infection, puromycin (0.5 μg/ml) was added for selection and maintained throughout the culturing period.

**RT-PCR**

One million cells were grown in 1.2 ml Matrigel on a 30-mm plate for 10 days (for T4-2 Rev, 350 nM AG1478 was added). The medium was removed and cells were scraped off from the dish with 2 ml PBS with 5 mM EDTA. They were then spun down to harvest the cell pellet and repeatedly washed with PBS + EDTA until Matrigel was dissolved. The total RNA was extracted with 1 ml Trizol (ThermoFisher Scientific). cDNA was synthesized from 2 μg RNA using the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen) and served as a template for PCR amplification with the respective primers (**Table 9**).

**Immunofluorescence staining**

Immunofluorescence was performed as described previously (**Weaver et al., 1997**). Samples were incubated with primary antibody for 2 hr at room temperature in a humidified chamber. After intensive washing (three times, 15 min each) in 0.1% BSA, 0.2% Triton-X 100, 0.05% Tween 20, 0.05% NaN3 in PBS, fluorescence-conjugated secondary antibodies (Molecular Probes) were added for 1 hr at room temperature. Nuclei were stained with 0.5 ng/ml DAPI.

**Soft agar assay**

One percent agar was mixed with the equivalent volume of 2x DMEM/F12 medium supplemented with all the additives necessary for culturing T4-2 cells (**Briand et al., 1996**) plus 20% FBS and 2% penicillin or streptomycin. 1 ml of the agar solution was poured into a 35 mm plate in triplicate and solidified. 0.7% agar solution equilibrated to 40°C was mixed with 2x growth medium and breast cancer cells at 7000 cells/ml and poured onto the base agar at 1 ml/plate. The solidified agar was covered with 500 μl growth medium and maintained in a 37°C humidified incubator for 14 d. The plates were stained with 0.01% crystal violet for 30 min, and colonies were counted under a dissecting microscope.

**Luciferase reporter assay**

For generation of miRNA reporter constructs, the promoter regions of miRNA genes were obtained by PCR-amplifying BAC genomic clones [miR-34c (Ch11), PR11-794P6; miR-30e (Ch1), RP11-576N9; miR-144 (Ch17), RP11-832J20] using the respective primers (**Table 9**) and inserted into the pGL3 luciferase expression vector. Cells seeded at 5 × 10⁵ cells/60-mm plate were transfected with 7 μg
of luciferase reporter and 0.5 μg of β-galactosidase plasmids using Xfect transfection reagent according to the manufacturer’s protocol (Clontech, Mountain View, CA, USA). After 24 hr post transfection, the medium was replaced with the fresh medium containing 5% Matrigel and cells were maintained for another 24 hr (for T4-2 Rev, 350 nM AG1478 was added). Luciferase and β-galactosidase reporter activities were measured using a reporter assay kit (Promega, Madison, WI, USA).

Decoy analysis
Wild-type miRNA decoy sequences (Table 7) were derived from the binding sites of NFκB or HOXD10 within the miRNA promoters predicted by AlGGEN PROMO software (see below). The sequence-specific binding of the two TFs was tested using mutant decoys (Table 7) that had point mutations in their core binding sequences. The forward and reverse oligonucleotides of decoys at 100 μM each were annealed in Duplex buffer (Integrated DNA Technologies, Coralville, IA, USA, CAT#11-05-01-12), and the same group of decoys was pooled. T4-2 cells were plated at 0.5 × 10^5/12 wells the day before transfection. NFκB decoys (scramble, WT or MT), along with miRNA promoters fused to luciferase (see above), were transfected into control T4-2 cells that had a high endogenous level of NFκB. HOXD10 decoys (scramble, WT or MT), along with promoter constructs, were transfected into T4-2 cells that overexpressed HOXD10. Transfection was performed with 1 μl XFect transfection reagent (Clontech, cat# 631318), 1.5 μg of promoter DNA and 200 nM of decoy oligonucleotides according to the manufacturer’s protocol. Cells were harvested at 48 hr post transfection. The luciferase activity was analyzed using the Bright-Glo Luciferase assay system (E2610, Promega) according to the manufacturer’s protocol, and the activity was normalized using protein concentration.

Analysis of transcription factor (TF) binding sites
TF binding sites within the promoter regions were predicted by AlGGEN PROMO software (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) (Farré et al., 2003). The feasibility of these predicted sites was indicated as the ‘Dissimilarity’ to the canonical sequence (0% as the best match). The significance of the predicted site was indicated as the ‘Frequency’ in the genomic background (‘Random Expectancy’ (RE) value x 10^-3) (Farré et al., 2003).

Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as described by Saccani et al. (2001) with a minor modification. Cells were plated at 2 × 10^6/100-mm plate and maintained overnight. Then, cells were maintained in the fresh medium containing 5% Matrigel for 24 hr (for T4-2 Rev, 350 nM AG1478 was added). Cells placed in fresh medium with 1% formaldehyde for 10 min, scraped off from the dish with PBS and processed for nuclear extraction. Chromatins were sonicated to ~500 bp fragments and
Figure 9. Activated p53 in turn upregulates expression of the endogenous alpha chain of LN5. (a) A schematic of the morphogenetic loop dissected to date with a predicted feedback loop between p53 and LN5. (b) The promoter region of the LAMA3 gene contained the CpG island that harbors numerous p53-binding sites around the transcription start site (TSS). (c) Representative result of western analysis (n = 3) for LAMA3 expression in T4-2 cells treated with a reverting agent (AG1478, LY294002 or PD98059) in the absence or presence of a p53 inhibitor, α-PFT. β-actin serves as a loading control. Fold difference was determined with respect to the Ctrl T4-2. *p<0.05; **p<0.01 and ***p<0.001. For each analysis, replicate experiments (n = 3) were performed, and representative data are shown. (d) Representative result of RT-PCR analysis (n = 3) showing that exogenous LN5 (1 μg/ml) upregulated LAMA3 transcription in MCF10A cells expressing wild-type p53, but not in cells expressing DNp53. α-tubulin (TUBA) was used as a control. Fold difference was determined with respect to time 0. *p<0.05; **p<0.01 and ***p<0.001. (e) (Left) Representative images of the IHC staining of breast cancer tissues (n = 117) for LAMA3 and wild-type p53. (Right) Correlation analysis between LAMA3 expression and wild-type p53 expression in breast tumors.

DOI: https://doi.org/10.7554/eLife.26148.032

The following figure supplement is available for figure 9:

Figure supplement 1. LAMA3 expression depends on p53 activation.

DOI: https://doi.org/10.7554/eLife.26148.033
Table 8. LAMA3 promoter regions harboring binding sites of p53.

| Promoter | TXN bound | Start nt from TSS | End nt from TSS | String | Dissimilarity (%) | Equally | Query |
|----------|------------|-------------------|-----------------|--------|-------------------|---------|-------|
| LAMA3    | p53        | -4245             | -4239           | TGGGCCC | 8.8               | 2 x 10^{-3} | 2 x 10^{-3} |
|          |            | -4143             | -4137           | GGGCCAGA | 1.7               | 9 x 10^{-4} | 8 x 10^{-4} |
|          |            | -4063             | -4057           | TCTGCCC | 1.7               | 9 x 10^{-4} | 8 x 10^{-4} |
|          |            | -3597             | -3591           | GGTGCC | 4                 | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -3585             | -3579           | CACGGCC | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -3451             | -3445           | GGGGCCC | 7.4               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | 813               | 819             | ACTGCCC | 3.5               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -4547             | -4541           | CTTGCC | 0.2               | 9 x 10^{-4} | 7 x 10^{-4} |
|          |            | -3094             | -3088           | TGAGGG | 6.7               | 2 x 10^{-3} | 2 x 10^{-3} |
|          |            | -2804             | -2798           | CACGGCC | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -2718             | -2712           | TCTGCCC | 1.7               | 9 x 10^{-4} | 8 x 10^{-4} |
|          |            | -2347             | -2341           | CCAGCCC | 3.7               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -2328             | -2322           | GGGCTCT | 8.5               | 3 x 10^{-4} | 2 x 10^{-4} |
|          |            | -1914             | -1908           | GTGCC | 6.4               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -1798             | -1792           | ACCGGCC | 6.8               | 2 x 10^{-3} | 2 x 10^{-3} |
|          |            | -948              | -942            | GTGCC | 6.4               | 1 x 10^{-3} | 9 x 10^{-4} |
|          |            | -437              | -431            | TCTGCCC | 1.7               | 9 x 10^{-4} | 8 x 10^{-4} |
|          |            | -420              | -414            | GGGCGGC | 6.1               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -374              | -368            | GGGCGGC | 3.5               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -355              | -349            | GGGCGGG | 4.6               | 6 x 10^{-4} | 4 x 10^{-4} |
|          |            | -342              | -336            | CTGGCCC | 4.3               | 6 x 10^{-4} | 4 x 10^{-4} |
|          |            | -325              | -319            | GGGCGGC | 6.9               | 2 x 10^{-3} | 2 x 10^{-3} |
|          |            | -314              | -308            | GGGCGG | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -310              | -304            | GGGCAGG | 0                 | 9 x 10^{-4} | 7 x 10^{-4} |
|          |            | -296              | -290            | GGGACA | 3                 | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -256              | -250            | GCAGCCC | 6.5               | 1 x 10^{-3} | 9 x 10^{-4} |
|          |            | -236              | -230            | TCAGCCC | 5.5               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -223              | -217            | TCTGCCC | 1.7               | 9 x 10^{-4} | 8 x 10^{-4} |
|          |            | -183              | -177            | TCAGCCC | 5.5               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -1127             | -1121           | GGGCGCC | 7.4               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -126              | -120            | GGGCCCA | 7.4               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -96               | -90             | GGGCCA | 6                 | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -85               | -79             | GGGCGG | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -75               | -69             | GGGCGG | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -70               | -64             | GGGCGG | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -65               | -59             | GGGGCA | 6.4               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -40               | -34             | GGGCGG | 6.1               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | -24               | -18             | GGGCGG | 6.1               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | 1                 | 7               | GGGCAG | 4.3               | 6 x 10^{-4} | 4 x 10^{-4} |
|          |            | 7                 | 13              | GGGCAG | 2.8               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | 45                | 51              | GGGCGG | 4.6               | 6 x 10^{-4} | 4 x 10^{-4} |
|          |            | 101               | 107             | GGGCGT | 3.3               | 1 x 10^{-3} | 1 x 10^{-3} |
|          |            | 155               | 161             | TGAGCC | 6.7               | 2 x 10^{-3} | 2 x 10^{-3} |

Table B continued on next page
immunoprecipitated with control rabbit IgG, HOXD10 and p65 antibodies at 4°C overnight. Chromatin-antibody complexes were washed with buffer 1 [0.1% SDS, 0.5% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl], buffer 2 [0.1% SDS, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 500 mM NaCl] then TE buffer [10 mM Tris-HCl (pH 8.0) 1 mM EDTA]. After reversal of cross-linking by heating at 65°C overnight, immunoprecipitated chromatin was subjected to PCR reaction for ~300 bp fragments around HOXD10/NFκB binding sites in miRNA promoters (miR-34c: ~0 kb, miR-30e: ~2 kb, miR-144: ~2 kb) with the appropriate primers (Table 9).

### Protein array

The relative abundance of the secreted laminin chains was determined with ImmunoCruz Cell Adhesion-2 MicroArray (sc-200006, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) according to the manufacturer’s protocol. Briefly, cells were plated at 2 × 10^6/100-mm plate and maintained overnight. Cells were maintained in the fresh medium containing 5% Matrigel for 24 hr. The CM was harvested and spun to remove the Matrigel drip. The medium was concentrated to 1 ml using Amicon Ultra-15 centrifugal filter units (3 kDa cut off, Millipore). The protein concentration was determined with DC Protein Assay reagent (Bio-Rad) and normalized to 1 mg/ml. 250 μg protein was labeled with Cy3 dye (Cy3 Mono-Reactive Dye Pack, GE Healthcare, Milwaukee, WI, USA). The labeled protein was dissolved in 1.5 ml desalting buffer, and unbound dye was removed by using Amicon Ultra-15 centrifugal filter units that concentrated the protein to 500 μl. The labeled protein was hybridized with array slides, and slides were scanned and analyzed by the CruzScan Scanning service (sc-200215, Santa Cruz).

### Immunohistochemistry

Breast cancer tissue arrays containing 150 paraffin-embedded sections of normal and malignant tissues with pathological information (stages I through III) were obtained from US Biomax, Inc (BR1503b). Slides were deparaffinized, hydrated, and treated with antigen unmasking solutions (Vector Laboratories, Inc.). After being blocked with 0.3% H₂O₂ and nonimmune goat serum, sections were incubated at room temperature with an antibody against S-nitrosocysteine (Abcam, Cambridge, MA, USA, clone HY8E12), human LAMA3 (R&D Systems, Minneapolis, MN, USA, , clone 546215) or wild-type human p53 (EMD Millipore, clone pAb1620) and link antibodies, followed by peroxidase-conjugated streptavidin complex and diaminobenzidine tetrahydroxy chloride solution as the peroxidase substrate (Vector Laboratories, Burlingame, CA, USA). The sections were counterstained with hematoxylin. Photomicrographs were taken with the Zeiss Axioskop Imaging platform and Axion Vision software (Version 4.7).

### MMP-9 measurement

MMP-9 secreted into CM was measured using the MMP-9 ELISA Kit (ThermoFisher Scientific) according to the manufacturer’s protocol. Assay samples were prepared in the dark. Briefly, cells were plated at 1 × 10^6/60-mm plate and maintained overnight. Cells were maintained in 2 ml of the fresh medium containing 5% Matrigel for 24 hr. The CM was harvested and spun to remove the

| Promoter | TXN bound | Start nt from TSS | End nt from TSS | String | Dissimilarity (%) | Equally | Query |
|----------|------------|-------------------|----------------|--------|-------------------|---------|-------|
| 160      | 166        | CCGGCC            | 4.1            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 216      | 222        | GGGGGG            | 3.3            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 200      | 206        | GGGGGG            | 3.3            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 206      | 212        | GGGGCGC           | 6.1            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 220      | 226        | AAAGGCC           | 7.2            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 236      | 242        | GGGCTGC           | 6.5            | 1 × 10⁻³ | 1 × 10⁻³          |         |       |
| 251      | 257        | GGGCCG            | 4.6            | 6 × 10⁻⁴ | 4 × 10⁻⁴          |         |       |

DOI: https://doi.org/10.7554/eLife.26148.034
Matrigel drip. The cleared CM was diluted 100-fold and analyzed for MMP-9 concentration using MMP-9 standards based on the optical density values at 450 nm.

**Nitrite/nitrate measurement**

To quantify the cumulative level of NO produced, the more stable oxidation product nitrite/nitrate was measured using the Measure-IT High-Sensitivity Nitrite Assay Kit (ThermoFisher Scientific) according to the manufacturer’s protocol. Assay samples were prepared in the dark. Briefly, cells were plated at 1 × 10^5/60-mm plate and maintained overnight. Cells were maintained in 2 ml of the fresh medium containing 5% Matrigel for the designated time periods. The CM was harvested and spun to remove the Matrigel drip. 10 μl of the cleared CM was analyzed for nitrite concentration using nitrite standards at the excitation/emission maxima of 340/410 nm.

**Detection of NO production in live cells**

To capture a snap shot of NO level in live cells after laminin addition, a dye DAF-FM DA (4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate, ThermoFisher Scientific) was used according to the manufacturer’s protocol. The signal intensity/area/cell was measured with ImageJ.

**Breast tissues and ex vivo 3D organoid cultures**

Breast tissues from reduction mammoplasties were obtained from the Cooperative Human Tissue Network (CHTN), a program funded by the National Cancer Institute. All specimens were collected with patient consent and were reported negative for proliferative breast disease by board-certified pathologists. Use of these anonymous samples was granted exemption status by the University of California at Berkeley Institutional Review Board according to the Code of Federal Regulations 45 CFR 46.101. Upon receipt, the tissues were rinsed with PBS, minced and incubated overnight with 0.1% collagenase as previously described (with gentle agitation) (Hines et al., 2015). The resulting
Table 9. List of oligonucleotide sequences of molecules listed in the manuscript.

### Northern probes

| miRNA        | Sequence                        |
|--------------|---------------------------------|
| miR-450b-5p  | 5'-TAT TCA GGA ACA TAT TGC AAA A-3' |
| miR-495      | 5'-AAG AAG TGC ACC ATG TTT GTT T-3' |
| miR-30e      | 5'-CTT CCA GTC AAG GAT GTT TAC A-3' |
| miR-330-3p   | 5'-CTG CAG GCC GTG TGC TTT GC-3' |
| miR-382      | 5'-CGA ATC CAC GAC GAA CAA CTT C-3' |
| miR-423-3p   | 5'-ACT GAG GGG CCT CAG ACC GAG CT-3' |
| miR-135a     | 5'-TCA CAT AGG AAT AAA AAG CCA TA-3' |
| miR-144      | 5'-AGT ACA TCA TCT ATA CTG TA-3' |
| miR-301b     | 5'-GCT TTG ACA ATA TCA TTG CAC TG-3' |
| miR-34c-5p   | 5'-GCA ATC AGC TAA CTA CAC TGC CT-3' |

### RT-PCR

| Gene        | Sense Sequence                        | Antisense Sequence                        |
|-------------|--------------------------------------|------------------------------------------|
| EIF5A2      | 5'-ATG GCA GAC GAA ATT GAT TTC ACT A-3' | 5'-CTC ATT GCA CAC ATG ACA GAC-3'        |
| SCA1        | 5'-ACG GTC ATT CAG ACC ACA CA-3'     | 5'-CAG GGT TGA AGT TCT CGC TC-3'         |
| ITGB1       | 5'-CGC CGC GCG GAA AAG ATG AAT-3'   | 5'-TGG GCT GTT GCA GTT TTC A-3'          |
| c-RAF       | 5'-CGA CCC ACA GTG GAC GAT CCA G-3' | 5'-AGA TAA TGC TGG CCG ACT GGC CT-3'    |
| MEK1        | 5'-AAG GGA ATC CCG GGC TGC CGA A-3' | 5'-GCC ATC GCT GTA GAA CGC ACC A-3'     |
| MAPK        | 5'-GCA CCG TGA CCT CAA GCC TTC-3'   | 5'-CAC CGA TGT CTG AGC ACG TCC AG-3'    |
| LAMA3       | 5'-GAT GGC TCA GGC ATA TGA TGT TT-3' | 5'-CTG GCC ATT GCT GTT ACA ACT-3'       |
| TUBA        | 5'-TGA CCT GAC AGA ATT CCA GAC CA-3' | 5'-GCA TTG ACA TCT TTG GGA ACC AC-3'   |

### shRNA

| Gene        | Sense Sequence                        | Antisense Sequence                        |
|-------------|--------------------------------------|------------------------------------------|
| EIF5A2sh    | 5'-GAT CGG CTG CCA GAA GGT GAA CTA GCT TCC TGT CAG ATA TAT TTC TCC CAC ACT TT TGT-3' | 5'-AAT TCA AAA ACT GCC AGA AGG TGA ACT AGT CTG ACA GGA AGT ATA TCT CTC CTT CCA CAC G-3' |

*shRNA (target sequence underlined; BamH1/EcoR1 cohesive ends italicized)*

*Furuta et al. eLife 2018;7:e26148. DOI: https://doi.org/10.7554/eLife.26148*
| Northern probes | Sense | 5'-GAT CGG AAC CTG AAG AAC GGC TCT CTT CCT GTC AGA AGA GGC GTT CTT CAG TGT CTT TGT TTT G-3' |
|-----------------|-------|--------------------------------------------------------------------------------------|
|                 | Antisense | 5'-AAT TCA AAA AGA ACC TGA AGA GCT CTT CTG ACA GGA AGA GAG CCG TTC TCC AGG TTC G-3' |
| p65sh | Sense | 5'-GAT CGG GAC ATA TGA GAC CTT CAA CTT CCT GTC AGA TTA GAG GTC TCA TAT GTC CTT TTT G-3' |
|                 | Antisense | 5'-AAT TCA AAA AGG ACA TAT GAG ACC TCC CAA GTG ACA GGA AGT TGA AGG TCT CAT ATG TCC G-3' |
| p50/p100sh | Sense | 5'-GAT CGG AGC TAA TCC GCC ACC CT CTT GTC AGA GGT AAT CCA GAA GGA CTC CCT TTT G-3' |
|                 | Antisense | 5'-AAT TCA AAA AGG AGT CCT CTA GGA AGT CTA AGT ACA GGA GAG GTG TAG TCT GTC G-3' |
| LAMA3sh | Sense | 5'-GAT CGG GAG TCC TTC TGG ATT ACC CT TCT GTC AGA GGT AAT CCA GAA GGA CTC CTT TTT G-3' |
|                 | Antisense | 5'-AAT TCA AAA AGG AGT CCT CTA GGA AGT CTA AGT ACA GGA GAG GTG TAG TCT GTC G-3' |

### Overexpressing constructs

**HOXD10**

| FW | 5'-CGG CAG GCG CGC CGC CAT GTC CTT TCC CAA CAG CTC TCC T-3' (AscI site italicized) |
| RV | 5'-CGG GCC GAA TTC CTA AGA AAA CGT GAG GTG GGT GGT CAG-3' (EcoR1 site italicized) |

**p53**

| FW | 5'-GAT CTC GGA TCC GCC ACC ATG GAG CAG CCG CAG TCA GAT CCT AGC-3' (BamH1 site italicized) |
| RV | 5'-TAC AGG AAT TCT CAG TCT GAG TCA GCC CCT TCT TCT GTC TTG AAC ATG-3' (EcoR1 site italicized) |

**ATXN1 and EIF5A2**

| FW | 5'-TCT AGA GCC CGG GCG CGC CGG CGG CGA TCG CCA TG-3' |
| RV | 5'-GCA GAT CCT TCG CGG CCG CT TAA ACC TTA TCG TCA TCA TTG TAA TCC AGG ATA TCA TTT GC-3' |

### miRNA reporter constructs (Mlu1/Xho1 sites italicized)

**miR-34c**

| 3-0 kb | FW | 5'-GAC TAC GCG TAC CGC TGG CAG TTT ATT TTA GCT C-3' (Mlu1 site italicized) |
|       | RV | 5'-GAC TCT CGA GCT AGA AGA TGG AGG CCC AGA TTC TTT AGA C-3' (Xho1 site italicized) |
| 2-0 kb | FW | 5'-GAC TAC GCG TCT TGG CTT CCT CCT ATG CAT CAA CCT-3' (Mlu1 site italicized) |
|       | RV | 5'-GAC TCT CGA GTC TGA TCT AGC AGG AGG GAC AAA GAG-3' (Xho1 site italicized) |
| 1-0 kb | FW | 5'-GAC TAC GCG TCT TCA TTA TGG GTA CAG AAG CAC-3' (Mlu1 site italicized) |
|       | RV | 5'-GAC TCT CGA GCT AGA AGA TGG AGG CCC AGA TTC TTT AGA C-3' (Xho1 site italicized) |
| 3-2 kb | FW | 5'-GAC TAC GCG TTT ATA AAA ACC GCT GGC AGT TCA TTT TAG C-3' (Mlu1 site italicized) |
|       | RV | 5'-GAC TCT CGA GAG GAG GAA GCC AAG AGT GTA GAA AAC A-3' (Xho1 site italicized) |
| 2-1 kb | FW | 5'-GAC TAC GCG TCT ATT CTC CCA CCT CAG CC TCC AAC TAG-3' (Mlu1 site italicized) |
|       | RV | 5'-GAC TCT CGA GCT GTA CAC CCC ATA ATG CAG GGA AAG AAA C-3' (Xho1 site italicized) |

Table 9 continued on next page
| Northern probes | miR-30e | miR-144 |
|-----------------|---------|---------|
| **3–0 kb**      | FW 5'-GAC TAC GCG TGC CAC CAT GCC CGG CTA A-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TCT CAA CAA GCA GTC TGA ATC TGA TGG TATTT ACC-3' (Xho site italicized) |
| RV 5'-GAC TCT CGA GGG GAG CTC GAG ATC TGA GTT TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA GTT TTG ACC-3' (Xho site italicized) |
| **2–0 kb**      | FW 5'-GAC TAC GCG TCT GTT CTT GA A CTG ACC TCG TCA ATG A-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TCT GTT CTT GA A CTG ACC TCG TCA ATG A-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA GTT TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA GTT TTG ACC-3' (Xho site italicized) |
| **1–0 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **3–2 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **2–1 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **miR-144**     | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **3–0 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **2–0 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **1–0 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **3–2 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **2–1 kb**      | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) | FW 5'-GAC TAC GCG TTT AGA TCT GGG TAC AGA TGA AGG AAT TGA GAC TCC-3' (Mlu site italicized) |
| RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) | RV 5'-GAC TCT CGA GTT CGG GAG CTC GAG ATC TGA TGG TTG ACC-3' (Xho site italicized) |
| **miR-34c**     | FW 5'-GTG TCA GCA ATG GGT GCT CTA-3' | FW 5'-GTG TCA GCA ATG GGT GCT CTA-3' |
| RV 5'-CCA GAG GAG GATG AGA CTT GAG-3' | RV 5'-CCA GAG GAG GATG AGA CTT GAG-3' |
| **miR-30a**     | FW 5'-GAG GCA GTC TGA GAT ATT CCC-3' | FW 5'-GAG GCA GTC TGA GAT ATT CCC-3' |
| RV 5'-CTG CAG CAT AAC ATG CTA GCT-3' | RV 5'-CTG CAG CAT AAC ATG CTA GCT-3' |
| **miR-144**     | FW 5'-CTG TGA TGA GGA CAA CAG TAA-3' | FW 5'-CTG TGA TGA GGA CAA CAG TAA-3' |
| RV 5'-ATC CCC CTA CCT CAG CCT CTC-3' | RV 5'-ATC CCC CTA CCT CAG CCT CTC-3' |

DOI: https://doi.org/10.7554/eLife.26148.036
divested tissue fragments (organoids) were rinsed with PBS and collected by centrifugation (100 g × 2 min). Lactiferous ducts and terminal ductal lobular units (TDLU) were individually isolated using a micromanipulator and drawn glass needles using a screw-actuated micrometer driven Hamilton syringe for suction/injection pressure. Single organoids were subsequently embedded in 50% growth factor reduced Matrigel (BD Biosciences) and overlayed with M87 growth medium. At 2 hr post seeding, medium was refreshed with L-NAME (NO inhibitor) containing medium at 5 mM. Cells were incubated at 37°C/5% CO₂. Medium was refreshed every other day for the length of the experiment (14 d).

**Live cell imaging and cell tracking**

Three-dimensional live cell imaging was performed using a Zeiss LSM 710 Meta confocal microscope and Zen Version 8.1 software. Cells were mixed with lreECM, seeded and covered along with complete growth media in a Lab-Tek 4-well chambered coverglass 2 hr prior to image capturing. Samples were placed in a 37 °C humidified microscope stage incubator with 5% CO₂. Images of 512 × 512 pixels in XY coordinates with a maximum Z-axis displacement of 75 μm were acquired using a 0.8 NA 20 × air objective at one frame/second. Images were captured successively at 20 min intervals for 48 hr. Samples were simultaneous excited by the 488 nm light (argon ion laser) at a power of <3% maximum and 546 nm light (a solid-state laser) at a power of <10% maximum. A secondary dichroic mirror was used in the emission pathway to separate the red (band-pass filters 560–575 nm) and green (band-pass filters 505–525 nm) channels. Gain was set between 100 and 180. Processed data were imported into Imaris (Bitplane, South Windsor, CT, USA), and nuclei were modeled (detection diameter: 5,800–6,500 nm). The nuclei were tracked over time using the tracking function of Imaris with the maximum distance of 2,500–20,000 nm and the maximum gap size of 1.

**Statistics**

Unless otherwise indicated, statistical analyses were performed using Graph Pad Prism Version 5 software and an unpaired two-tailed Student’s t-test for parametric tests and Spearman correlation analysis for non-parametric tests. P-values of 0.05 or less were considered significant. Average results of multiple experiments (n > 3) are presented as the arithmetic mean ± SEM.

**Acknowledgements**

We thank all members of the Bissell Laboratory for constructive comments. In particular, we would like to thank Dr Curt Hines, Kremena Karagyozova and Kate Thi for providing normal human breast tissues and preparing ex vivo organotypic cultures. We also would like to thank Drs. Eva Lee and Alvin Lo in the Bissell laboratory and Samantha Metzger and Matthew Bommarito in the Furuta laboratory for their excellent technical support. The authors thank Dr Sun-Young Lee for helping with the accuracy of the galley and additional suggestions for improvement. The authors thank Sarah J Lee for her excellent administrative assistance with the many changes required during the final stages of manuscript preparation and galley proofing. This work was supported by grants from the US Department of Defense Innovator Expansion Award (W81XWH0810736); Breast Cancer Research Foundation (BCRF); multiple grants from the NCI (R01CA064786; U01CA143233, U54CA112970 and U54CA143836 – Bay Area Physical Sciences Oncology Center) to MJB; and in part by the University of Toledo Department of Cancer Biology Startup Fund and an Ohio Cancer Research Grant (Project #: 5017) to SF.

**Additional information**

**Funding**

| Funder                        | Grant reference number | Author         |
|-------------------------------|------------------------|----------------|
| Ohio Cancer Research          | 5017                   | Saori Furuta   |
| National Cancer Institute     | R01CA064786            | Mina J Bissell |
| U.S. Department of Defense    | W81XWH0810736          | Mina J Bissell |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**
Saori Furuta, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing; Gang Ren, Data curation, Performed the experiments for revision, Acquired and analysed data; Jian-Hua Mao, Data curation, Formal analysis, Writing—review and editing, Performed statistical analyses and provided primary tissues; Mina J Bissell, Conceptualization, Resources, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing

**Author ORCIDs**
Saori Furuta [https://orcid.org/0000-0003-1121-0487](https://orcid.org/0000-0003-1121-0487)
Mina J Bissell [http://orcid.org/0000-0001-5841-4423](http://orcid.org/0000-0001-5841-4423)

**Decision letter and Author response**
Decision letter [https://doi.org/10.7554/eLife.26148.043](https://doi.org/10.7554/eLife.26148.043)
Author response [https://doi.org/10.7554/eLife.26148.044](https://doi.org/10.7554/eLife.26148.044)

**Additional files**

**Supplementary files**
- Transparent reporting form
  DOI: [https://doi.org/10.7554/eLife.26148.037](https://doi.org/10.7554/eLife.26148.037)

**Major datasets**
The following previously published dataset was used:

| Author(s)                        | Year | Dataset title                                      | Dataset URL                                      | Database, license, and accessibility information |
|----------------------------------|------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Becker-Weimann S, Bissell MU, Ono-dera Y, Rizki A | 2013 | Gene expression in organized and disorganized human breast epithelial cells | [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50444](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50444) | Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE50444) |

**References**
Adriance MC, Inman JL, Petersen OW, Bissell MJ. 2005. Myoepithelial cells: good fences make good neighbors. Breast Cancer Research 7:190–197. DOI: [https://doi.org/10.1186/bcr1286](https://doi.org/10.1186/bcr1286), PMID: 16168137

Akcay F, Aksoy H, Memisogullari R. 2002. Effect of breast-feeding on concentration of nitric oxide in breast milk. Annals of Clinical Biochemistry 39:68–69. DOI: [https://doi.org/10.1258/0004563021901595](https://doi.org/10.1258/0004563021901595), PMID: 11853194

Akhavan A, Griffith OL, Sorocauan L, Leonoudakis D, Luciani-Torres MG, Daemen A, Gray JW, Muschler JL. 2012. Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Research 72:2578–2588. DOI: [https://doi.org/10.1158/0008-5472.CAN-11-3732](https://doi.org/10.1158/0008-5472.CAN-11-3732), PMID: 22589276

Barcellos-Hoff MH, Agerler J, Ram TG, Bissell MJ. 1989. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 105:223–235. PMID: 2806122

Becker-Weimann S, Xiong G, Furuta S, Han J, Kuhn I, Akavia UD, Pe’er D, Bissell MJ, Xu R. 2013. NFκB disrupts tissue polarity in 3D by preventing integration of microenvironmental signals. Oncotarget 4:2010–2020. DOI: [https://doi.org/10.18632/oncotarget.1451](https://doi.org/10.18632/oncotarget.1451), PMID: 24243820
Furuta et al. eLife 2018;7:e26148. DOI: https://doi.org/10.7554/eLife.26148

Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, Muschler J, Bissell MJ. 2010. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes & Development 24:2800–2811. DOI: https://doi.org/10.1101/gad.1990410, PMID: 21159820

Bhat R, Bissell MJ. 2014. Of plasticity and specificity: dialectics of the micro- and macro-environment and the organ phenotype. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 3:147–163. DOI: https://doi.org/10.1002/2010103070130, PMID: 24678448

Bissell MJ, Hall HG, Parry G. 1982. How does the extracellular matrix direct gene expression? Journal of Theoretical Biology 99:31–68. DOI: https://doi.org/10.1016/0022-5193(82)90388-5, PMID: 6892044

Bissell MJ, Hines WC. 2011. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine 17:320–329. DOI: https://doi.org/10.1038/nm.2328, PMID: 21383745

Bissell MJ, Kenny PA, Radisky DC. 2005. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harbor Symposia on Quantitative Biology 70:343–356. DOI: https://doi.org/10.1101/sqb.2005.70.013, PMID: 16869771

Bissell MJ, Rizki A, Mian IS. 2003. Tissue architecture: the ultimate regulator of breast epithelial function. Current Opinion in Cell Biology 15:753–762. DOI: https://doi.org/10.1016/jceb.2003.10.016, PMID: 14644202

Bissell MJ. 1981. The differentiated state of normal and malignant cells or how to define a "normal" cell in culture. International Review of Cytology 70:27–100, PMID: 7229573

Briaud P, Nielsen KV, Madsen MW, Petersen OW. 1996. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Research 56:2039–2044. PMID: 8616848

Briaud P, Petersen OW, Van Deurs B. 1987. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cellular & Developmental Biology 23:181–188. DOI: https://doi.org/10.1007/BF02623578, PMID: 3558253

Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Silicano JD. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677–1679. DOI: https://doi.org/10.1126/science.281.5383.1677, PMID: 9733515

Chamoux E, Narcy A, Lehoux JG, Gallo-Payet N. 2002. Fibronectin, laminin, and collagen IV as modulators of cell behavior during adrenal gland development in the human fetus. The Journal of Clinical Endocrinology & Metabolism 87:1819–1828. DOI: https://doi.org/10.1210/jecl.87.4.8359, PMID: 11932324

Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. 1999. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. PNAS 96:13777–13782. DOI: https://doi.org/10.1073/pnas.96.24.13777, PMID: 10570149

Chen A, Cuevas I, Kenny PA, Miyake H, Mace K, Ghajar C, Boudreau A, Bissell MJ, Bissell M, Boudreau N. 2009. Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity. Cancer Research 69:6721–6729. DOI: https://doi.org/10.1158/0008-5472.CAN-08-4069, PMID: 19654314

Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. 1986. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47:131–139. DOI: https://doi.org/10.1016/0092-8674(86)90374-0, PMID: 2428505

Daley WP, Yamada KM. 2013. ECM-modulated cellular dynamics as a driving force for tissue morphogenesis. Current Opinion in Genetics & Development 23:408–414. DOI: https://doi.org/10.1016/j.gde.2013.05.005, PMID: 23849799

Esser AK, Miller MR, Huang Q, Meier MM, Beltran-Valero de Bernabé D, Stipp CS, Campbell KP, Lynch CF, Smith BJ, Cohen MB, Henry MD. 2013. Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer. Journal of Biological Chemistry 288:2132–2142. DOI: https://doi.org/10.1074/jbc.M112.432807, PMID: 23223448

Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albá MM, Messeguer X. 2003. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Research 31:3651–3653. DOI: https://doi.org/10.1093/nar/gkg605, PMID: 12824386

Fiore A, Spencer VA, Mori H, Carvalho HF, Bissell MJ, Bruni-Cardoso A. 2017. Laminin-111 and the level of nuclear actin regulate epithelial quiescence via exportin-6. Cell reports 19:2102–2115. DOI: https://doi.org/10.1016/j.crep.2017.05.050, PMID: 28591581

Forrester K, Ambis S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC. 1996. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. PNAS 93:2442–2447. DOI: https://doi.org/10.1073/pnas.93.6.2442, PMID: 8637893

Garbincius JF, Michele DE. 2015. Dystrophin-glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling. PNAS 112:13663–13668. DOI: https://doi.org/10.1073/pnas.1512991112, PMID: 26483453

Gloe T, Pohl U. 2002. Laminin-binding conveys mechanosensing in endothelial cells. Physiology 17:166–169. DOI: https://doi.org/10.1152/physiol.01381.2001, PMID: 12136046

Gloe T, Riedmayr S, Sohn HY, Pohl U. 1999. The 67-kDa laminin-binding protein is involved in shear stress-dependent endothelial nitric-oxide synthase synthesis. Journal of Biological Chemistry 274:15996–16002. DOI: https://doi.org/10.1074/jbc.274.23.15996, PMID: 10347148
Furuta et al. eLife 2018;7:e26148. DOI: https://doi.org/10.1056/ncomms7927, PMID: 25896888

Gordon SA, Abou-Jaoude W, Hoffman RA, McCarthy SA, Kim YM, Zhou X, Zhang XR, Simmons RL, Chen Y, Schall L, Ford HR. 2001. Nitric oxide induces murine thymocyte apoptosis by oxidative injury and a p53-dependent mechanism. Journal of leukocyte biology 70:87–95. PMID: 11435490

Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H. 2013. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. Journal of Biological Chemistry 288:26473–26479. DOI: https://doi.org/10.1074/jbc.R113.460261, PMID: 23861393

Gudjonsson T, Rannov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. 2002. Normal and tumour-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. Journal of cell science 115:39–50. PMID: 11801722

Hagios C, Lochter A, Bissell MJ. 1998. Tissue architecture: the ultimate regulator of epithelial function? Philosophical Transactions of the Royal Society B: Biological Sciences 353:857–870. DOI: https://doi.org/10.1098/rstb.1998.0250, PMID: 9684283

Haigo SL, Bilder D. 2011. Global tissue revolutions in a morphogenetic movement controlling elongation. Science 331:1071–1074. DOI: https://doi.org/10.1126/science.1199424, PMID: 21212324

Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics 9:305–311. DOI: https://doi.org/10.1038/ng0935-305, PMID: 7773294

Hines WC, Yaswen P, Bissell MJ. 2015. Modelling breast cancer requires identification and correction of a critical cell lineage-dependent transduction bias. Nature Communications 6:6972. DOI: https://doi.org/10.1038/ncomms7927, PMID: 25896888

Hogan BL. 1999. Morphogenesis. Cell 96:225–233. DOI: https://doi.org/10.1016/S0092-8674(00)80562-0, PMID: 9988217

Hord NG, Ghanam JS, Garg HK, Berens PD, Bryan NS. 2011. Nitrate and nitrite content of human, formula, bovine, and soy milks: implications for dietary nitrate and nitrite recommendations. Breastfeeding Medicine 6:393–399. DOI: https://doi.org/10.1089/bfm.2010.0070, PMID: 20958096

Howlett AR, Bissell MJ. 1993. The influence of tissue microenvironment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithelial Cell Biology 2:79–89. PMID: 8353596

Iizuka T, Sasaki M, Oishi K, Uemura S, Koike M. 1998. The presence of nitric oxide synthase in the mammary glands of lactating rats. Pediatric Research 44:197–200. DOI: https://doi.org/10.1203/00006450-199808000-00010, PMID: 9702914

Islam MS, Matsumoto M, Tsuchida K, Ota K, Kanouchi H, Suzuki S. 2009. Immunohistochemical localization of nitric oxide synthase (NOS) in mouse mammary gland during reproductive cycle. Journal of Veterinary Medical Science 71:945–949. DOI: https://doi.org/10.1292/jvms.71.945, PMID: 19652483

Ikawaki Y, Satoh A, Chatterjee S, Toomre DK, Chalouini CM, Fulton D, Groszmann RJ, Shah VH, Sessa WC. 2006. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. PNAS 103:19777–19782. DOI: https://doi.org/10.1073/pnas.0605907103, PMID: 17170139

Jabbur JR, Huang P, Zhang W. 2000. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene 19:6203–6208. DOI: https://doi.org/10.1080/0140724000200103, PMID: 11175334

Jorgens DM, Inman JL, Wojcik M, Robertson C, Palsdottir H, Tsai WT, Huang H, Bruni-Cardoso A, Lopez CS, Bissell MJ, Xu K, Auer M. 2009. Deep nuclear invaginations are linked to cytoskeletal filaments - integrated bioimaging of epithelial cells in 3D culture. Journal of Cell Science 130:177–189. DOI: https://doi.org/10.1242/jcs.190967, PMID: 27505896

Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ, Li G. 2014. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. British Journal of Cancer 110:399–408. DOI: https://doi.org/10.1038/bjc.2013.688, PMID: 24178756

Kim SW, Wu G. 2009. Regulatory role for amino acids in mammary gland growth and milk synthesis. Amino Acids 37:89–95. DOI: https://doi.org/10.1007/s00726-008-0151-5, PMID: 18683019

Komarova PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. 1999. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733–1737. DOI: https://doi.org/10.1126/science.285.5434.1733, PMID: 10481009

Lee GY, Kenny PA, Lee EH, Bissell MJ. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nature Methods 4:359–365. DOI: https://doi.org/10.1038/nmeth1015, PMID: 17396127

Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R, Bissell MJ. 2012. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. Journal of Clinical Investigation 122:3211–3220. DOI: https://doi.org/10.1172/JCI60498, PMID: 22886303

Liu E, Thant AA, Kikkawa F, Kurata H, Tanaka S, Nawa A, Mitzutani S, Matsuda S, Hanafusa H, Hamaguchi M. 2000. The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1. Cancer Research 60:2361–2364. PMID: 10811109

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834–838. DOI: https://doi.org/10.1038/nature03702, PMID: 15944708

Miner JH, Yurchenco PD. 2004. Laminin functions in tissue morphogenesis. Annual Review of Cell and Developmental Biology 20:255–284. DOI: https://doi.org/10.1146/annurev.cellbio.20.010403.094555, PMID: 15473841
Furuta et al. eLife 2018;7:e26148. DOI: https://doi.org/10.7554/eLife.26148

Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ, Orth AP, Chanda SK, Evans RM, Verma IM. 2011. Tumor suppressor protein (p)S3, is a regulator of NF-kappaB repression by the glucocorticoid receptor. *PNAS* **108**:17117–17122. DOI: https://doi.org/10.1073/pnas.1114420108, PMID: 21949408

Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ. 2002. A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. *Cancer research* **62**:7102–7109. PMID: 12460932

Niedbala W, Wei XQ, Campbell C, Thomson D, Komi-Koma M, Liew FY. 2002. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. *PNAS* **99**:16186–16191. DOI: https://doi.org/10.1073/pnas.252465499, PMID: 12451176

Oktay K, Karkkaya G, Akman O, Ojakian GK, Oktay M. 2000. Interaction of extracellular matrix and activin-A in the initiation of follicle growth in the mouse ovary. *Biological Reproduction* **63**:457–461. DOI: https://doi.org/10.1095/biolreprod63.2.457, PMID: 10906050

Osako MK, Nakagami H, Morishita R. 2012. Development and modification of decoy oligodeoxynucleotides for clinical application. *Advances in Polymer Science = Fortschritte Der Hochpolymeren-Forschung* **249**:49–60.

Park J, Al-Ramahi I, Tan Q, Mollena M, Diaz-Garcia JR, Gallego-Flores T, Lu HC, Lagalwar S, Duvick L, Kang H, Lee Y, Jafar-Nejad P, Sayegh LS, Richman R, Liu X, Gao Y, Shaw CA, Arthur JSC, Orr HT, Westbrook TF, et al. 2013. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. *Nature* **498**:325–331. DOI: https://doi.org/10.1038/nature12204, PMID: 23719381

Petersen OW, Rannov-Jessen L, Howlett AR, Bissell MJ. 1992. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. *PNAS* **89**:9064–9068. DOI: https://doi.org/10.1073/pnas.89.19.9064, PMID: 1384042

Petersen OW, Rannov-Jessen L, Weaver VM, Bissell MJ. 1998. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy. *Advances in Cancer Research* **75**:135–161, PMID: 9709809

Rando TA. 2001. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. *Muscle & Nerve* **24**:1575–1594. DOI: https://doi.org/10.1002/mus.1192, PMID: 11745966

Rialas CM, Nomizu M, Patterson M, Kleinman HK, Weston CA, Weeks BS. 2000. Nitric oxide mediates laminin-induced neurite outgrowth in PC12 cells. *Experimental Cell Research* **260**:268–276. DOI: https://doi.org/10.1006/excr.2000.5017, PMID: 11035921

Ricca BL, Venugopalan G, Furuta S, Tanner K, Orellana WA, Reber CD, Brownfield DG, Bissell MJ, Fletcher DA. 2018. Transient external force induces phenotypic reversion of malignant epithelial structures via nitric oxide signaling. *eLife* **26161**. DOI: https://doi.org/10.7554/eLife.26161

Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ. 2008. A human breast cancer cell model of preinvasive to invasive transition. *Cancer Research* **68**:1378–1387. DOI: https://doi.org/10.1158/1078-0432.CAN-07-2225, PMID: 18316601

Rizzoni S, Meissner G. 2001. Two waves of nuclear factor kappaB recruitment to target promoters. *The Journal of Experimental Medicine* **193**:1351–1360. DOI: https://doi.org/10.1084/jem.193.12.1351, PMID: 11413190

Sasaki CY, Barberi TJ, Ghosh P, Longo DL. 2005. Phosphorylation of RelA/p65 on serine 536 defines an I(kappa)B(alpha)-independent NF-(kappa)B pathway. *Journal of Biological Chemistry* **280**:34538–34547. DOI: https://doi.org/10.1074/jbc.M504943200, PMID: 16105840

Spencer VA, Costes S, Inman JL, Xu R, Chen J, Hendzel MJ, Bissell MJ. 2011. Depletion of nuclear actin is a key mediator of quiescence in epithelial cells. *Journal of Cell Science* **124**:123–132. DOI: https://doi.org/10.1242/jcs.073197, PMID: 21172822

Stamler JS, Meissner G. 2001. Physiology of nitric oxide in skeletal muscle. *Physiological Reviews* **81**:209–237. DOI: https://doi.org/10.1152/physrev.2001.81.1.209, PMID: 1152758

Struehl C, Bissell MJ. 1990. Expression of extracellular matrix components is regulated by substratum. *The Journal of Cell Biology* **110**:1405–1415. DOI: https://doi.org/10.1083/jcb.110.4.1405, PMID: 2182652

Tanner K, Mori H, Mroue R, Bruni-Cardoso A, Bissell MJ. 2012. Coherent angular motion in the establishment of multicellular architecture of glandular tissues. *PNAS* **109**:1973–1978. DOI: https://doi.org/10.1073/pnas.1119578109, PMID: 22308439

Tezer M, Ozluk Y, Sanli O, Asoglu O, Kadioglu A. 2012. Nitric oxide may mediate nipple erection. *Journal of Andrology* **33**:805–810. DOI: https://doi.org/10.2164/jandrol.111.014951, PMID: 22207705

Wang J, Lacoche S, Huang L, Xue B, Muthuswamy SK. 2013. Rotational motion during three-dimensional morphogenesis of mammary epithelial acini relates to laminin matrix assembly. *PNAS* **110**:163–168. DOI: https://doi.org/10.1073/pnas.1201141110, PMID: 23248267

Wang X, Michael D, de Murcia G, Oren M. 2002. p53 Activation by nitric oxide involves down-regulation of Mdm2. *Journal of Biological Chemistry* **277**:15697–15702. DOI: https://doi.org/10.1074/jbc.M112068200, PMID: 11867628

Wang X, Zalcenstein A, Oren M. 2003. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. *Cell Death & Differentiation* **10**:468–476. DOI: https://doi.org/10.1038/sj.cdd.4401181, PMID: 12719724

Weaver VM, Leilievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. 2002. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. *Cancer Cell* **2**:205–216. DOI: https://doi.org/10.1016/S1535-6108(02)00125-3, PMID: 12242153
Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. 1997. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. The Journal of Cell Biology 137:231–245. DOI: https://doi.org/10.1083/jcb.137.1.231, PMID: 9105051

Webster GA, Perkins ND. 1999. Transcriptional cross talk between NF-kappaB and p53. Molecular and Cellular Biology 19:3485–3495. DOI: https://doi.org/10.1128/MCB.19.5.3485, PMID: 10207072

Weir ML, Oppizzi ML, Henry MD, Onishi A, Campbell KP, Bissell MJ, Muschler JL. 2006. Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring. Journal of Cell Science 119:4047–4058. DOI: https://doi.org/10.1242/jcs.03103, PMID: 16968749

Wessells N. 1977. Interaction in Development. Menlo Park: W.A. Benjamin, Inc.

Wockel A, Baum O, Planitzer G, Rothen-Rutishauser B, Gossrau R, Abou-Dakn M. 2005. Constitutive coexpression of nitric oxide synthase-1 and soluble guanylyl cyclase in myoepithelial cells of mammary glands in mice. Cells Tissues Organs 180:178–184. DOI: https://doi.org/10.1159/000088246, PMID: 16260864

Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734. DOI: https://doi.org/10.1016/S0092-8674(00)81401-4, PMID: 9529249